US5800815A
(en)
*
|
1903-05-05 |
1998-09-01 |
Cytel Corporation |
Antibodies to P-selectin and their uses
|
US5851526A
(en)
*
|
1985-04-19 |
1998-12-22 |
Ludwig Institute For Cancer Research |
Methods of treating colon cancer utilizing tumor-specific antibodies
|
US5449760A
(en)
*
|
1987-12-31 |
1995-09-12 |
Tanox Biosystems, Inc. |
Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
|
US5530101A
(en)
*
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
US7247453B1
(en)
*
|
1988-12-30 |
2007-07-24 |
Oklahoma Medical Research Foundation |
Calcium binding recombinant antibody against protein C
|
DE3900534A1
(de)
*
|
1989-01-10 |
1990-07-12 |
Boehringer Mannheim Gmbh |
Diagnostischer nachweis unter verwendung von chimaeren antikoerpern
|
US6750325B1
(en)
|
1989-12-21 |
2004-06-15 |
Celltech R&D Limited |
CD3 specific recombinant antibody
|
US5859205A
(en)
*
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
GB8928874D0
(en)
*
|
1989-12-21 |
1990-02-28 |
Celltech Ltd |
Humanised antibodies
|
GR1001050B
(el)
*
|
1990-01-09 |
1993-04-28 |
Protein Design Labs Inc |
Νεος il-2 υποδοχευς ιδιαζοντων ανθρωπινων ανοσοσφαιρινων.
|
HUT60768A
(en)
|
1990-03-16 |
1992-10-28 |
Sandoz Ag |
Process for producing cd25 fixing molecules
|
GB9020282D0
(en)
|
1990-09-17 |
1990-10-31 |
Gorman Scott D |
Altered antibodies and their preparation
|
US5858725A
(en)
*
|
1990-10-10 |
1999-01-12 |
Glaxo Wellcome Inc. |
Preparation of chimaeric antibodies using the recombinant PCR strategy
|
US5994510A
(en)
*
|
1990-12-21 |
1999-11-30 |
Celltech Therapeutics Limited |
Recombinant antibodies specific for TNFα
|
ATE247168T1
(de)
*
|
1991-03-06 |
2003-08-15 |
Merck Patent Gmbh |
Humanisierte monoklonale antikörper
|
IE920716A1
(en)
*
|
1991-03-07 |
1992-09-09 |
Gen Hospital Corp |
Redirection of cellular immunity by receptor chimeras
|
WO1992017505A1
(en)
*
|
1991-04-05 |
1992-10-15 |
Board Of Regents Of The University Of Washington |
Monoclonal antibodies to stem cell factor receptors
|
DE69229482T2
(de)
*
|
1991-04-25 |
1999-11-18 |
Chugai Pharmaceutical Co Ltd |
Rekombinierte humane antikörper gegen den humanen interleukin 6-rezeptor
|
DE69233482T2
(de)
*
|
1991-05-17 |
2006-01-12 |
Merck & Co., Inc. |
Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
|
US6800738B1
(en)
|
1991-06-14 |
2004-10-05 |
Genentech, Inc. |
Method for making humanized antibodies
|
WO1994004679A1
(en)
*
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
EP1400536A1
(en)
|
1991-06-14 |
2004-03-24 |
Genentech Inc. |
Method for making humanized antibodies
|
GB9115010D0
(en)
*
|
1991-07-11 |
1991-08-28 |
Wellcome Found |
Antibody
|
GB9115364D0
(en)
|
1991-07-16 |
1991-08-28 |
Wellcome Found |
Antibody
|
US5756096A
(en)
*
|
1991-07-25 |
1998-05-26 |
Idec Pharmaceuticals Corporation |
Recombinant antibodies for human therapy
|
MX9204374A
(es)
*
|
1991-07-25 |
1993-03-01 |
Idec Pharma Corp |
Anticuerpo recombinante y metodo para su produccion.
|
US5709860A
(en)
*
|
1991-07-25 |
1998-01-20 |
Idec Pharmaceuticals Corporation |
Induction of cytotoxic T-lymphocyte responses
|
US6136310A
(en)
|
1991-07-25 |
2000-10-24 |
Idec Pharmaceuticals Corporation |
Recombinant anti-CD4 antibodies for human therapy
|
CZ288048B6
(cs)
*
|
1991-07-25 |
2001-04-11 |
Idec Pharmaceuticals Corporation |
Farmaceutická kompozice k indukci cytotoxické odpovědi T-lymfocytů
|
US6329509B1
(en)
*
|
1991-08-14 |
2001-12-11 |
Genentech, Inc. |
Anti-IgE antibodies
|
US6699472B2
(en)
|
1991-08-14 |
2004-03-02 |
Genentech, Inc. |
Method of treating allergic disorders
|
DE69230545T2
(de)
*
|
1991-08-21 |
2000-07-06 |
Novartis Ag |
Antikörperderivate
|
GB9120467D0
(en)
*
|
1991-09-26 |
1991-11-06 |
Celltech Ltd |
Anti-hmfg antibodies and process for their production
|
JP3024311B2
(ja)
*
|
1991-10-03 |
2000-03-21 |
味の素株式会社 |
Il−2受容体重鎖に結合するポリペプチド
|
US7070777B1
(en)
|
1991-11-15 |
2006-07-04 |
The Trustees Of Columbia University In The City Of New York |
Method for inhibiting inflammation with an antibody that binds the 5C8 protein
|
US5474771A
(en)
|
1991-11-15 |
1995-12-12 |
The Trustees Of Columbia University In The City Of New York |
Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
|
US5817310A
(en)
*
|
1991-12-02 |
1998-10-06 |
Cor Therapeutics, Inc. |
Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
|
JPH05244982A
(ja)
*
|
1991-12-06 |
1993-09-24 |
Sumitomo Chem Co Ltd |
擬人化b−b10
|
US5869619A
(en)
*
|
1991-12-13 |
1999-02-09 |
Xoma Corporation |
Modified antibody variable domains
|
DE69233204T2
(de)
*
|
1991-12-13 |
2004-07-15 |
Xoma Corp., Berkeley |
Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
|
US5777085A
(en)
*
|
1991-12-20 |
1998-07-07 |
Protein Design Labs, Inc. |
Humanized antibodies reactive with GPIIB/IIIA
|
US5824307A
(en)
|
1991-12-23 |
1998-10-20 |
Medimmune, Inc. |
Human-murine chimeric antibodies against respiratory syncytial virus
|
WO1993016185A2
(en)
*
|
1992-02-06 |
1993-08-19 |
Creative Biomolecules, Inc. |
Biosynthetic binding protein for cancer marker
|
GB9203459D0
(en)
*
|
1992-02-19 |
1992-04-08 |
Scotgen Ltd |
Antibodies with germ-line variable regions
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
US5387676A
(en)
*
|
1992-03-11 |
1995-02-07 |
Ciba Corning Diagnostics Corp. |
MN gene and protein
|
US7381803B1
(en)
|
1992-03-27 |
2008-06-03 |
Pdl Biopharma, Inc. |
Humanized antibodies against CD3
|
US6129914A
(en)
|
1992-03-27 |
2000-10-10 |
Protein Design Labs, Inc. |
Bispecific antibody effective to treat B-cell lymphoma and cell line
|
US6033667A
(en)
*
|
1992-05-05 |
2000-03-07 |
Cytel Corporation |
Method for detecting the presence of P-selectin
|
US5874082A
(en)
*
|
1992-07-09 |
1999-02-23 |
Chiron Corporation |
Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
|
US5397703A
(en)
*
|
1992-07-09 |
1995-03-14 |
Cetus Oncology Corporation |
Method for generation of antibodies to cell surface molecules
|
US5639641A
(en)
*
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
US5958708A
(en)
*
|
1992-09-25 |
1999-09-28 |
Novartis Corporation |
Reshaped monoclonal antibodies against an immunoglobulin isotype
|
US6066718A
(en)
*
|
1992-09-25 |
2000-05-23 |
Novartis Corporation |
Reshaped monoclonal antibodies against an immunoglobulin isotype
|
GB9223377D0
(en)
*
|
1992-11-04 |
1992-12-23 |
Medarex Inc |
Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
|
CA2149326C
(en)
*
|
1992-11-13 |
2007-04-17 |
Mitchell E. Reff |
Fully impaired consensus kozak sequences for mammalian expression
|
US5648267A
(en)
*
|
1992-11-13 |
1997-07-15 |
Idec Pharmaceuticals Corporation |
Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
|
ATE196606T1
(de)
|
1992-11-13 |
2000-10-15 |
Idec Pharma Corp |
Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma
|
US7744877B2
(en)
|
1992-11-13 |
2010-06-29 |
Biogen Idec Inc. |
Expression and use of anti-CD20 Antibodies
|
US5736137A
(en)
*
|
1992-11-13 |
1998-04-07 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
US5804187A
(en)
*
|
1992-11-16 |
1998-09-08 |
Cancer Research Fund Of Contra Costa |
Modified antibodies with human milk fat globule specificity
|
DK0678122T3
(da)
|
1993-01-12 |
2000-03-06 |
Biogen Inc |
Rekombinante anti-VLA4 antistofmolekyler
|
US5730979A
(en)
*
|
1993-03-05 |
1998-03-24 |
Universite Catholique Delouvain |
LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation
|
US5817311A
(en)
*
|
1993-03-05 |
1998-10-06 |
Universite Catholique De Louvain |
Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies
|
US5951983A
(en)
*
|
1993-03-05 |
1999-09-14 |
Universite Catholique De Louvain |
Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies
|
EP0804235A4
(en)
*
|
1993-05-04 |
2001-09-19 |
Aeres Biomedical Ltd |
ANTIBODIES AGAINST SELECTIN P AND USES THEREOF
|
AU695124B2
(en)
*
|
1993-05-28 |
1998-08-06 |
Scripps Research Institute, The |
Methods and compositions for inhibiting CD14 mediated cell activation
|
ZA943778B
(en)
*
|
1993-05-31 |
1995-02-21 |
Chugai Seiyaku Kagushiki Kaish |
Reshaped human antibody to human interleukin-6
|
US6180377B1
(en)
*
|
1993-06-16 |
2001-01-30 |
Celltech Therapeutics Limited |
Humanized antibodies
|
HU222041B1
(hu)
*
|
1993-09-07 |
2003-04-28 |
Smithkline Beecham Corporation |
Az IL4 által kőzvetített rendellenességek kezelésére használható rekombináns 1L4 antitestek, eljárás ezek előállítására, alkalmazására és az őket tartalmazó gyógyszerkészítmények
|
US5914110A
(en)
*
|
1993-09-07 |
1999-06-22 |
Smithkline Beecham Corporation |
Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
|
US20020193575A1
(en)
|
1993-09-07 |
2002-12-19 |
Smithkline Beecham P.L.C. |
Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
|
US5928904A
(en)
*
|
1993-09-07 |
1999-07-27 |
Smithkline Beecham Corporation |
DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
|
US6214973B1
(en)
|
1993-11-19 |
2001-04-10 |
Chugai Seiyaku Kabushiki Kaisha |
Reshaped human antibody to human medulloblastoma cells
|
AU2185195A
(en)
*
|
1993-11-30 |
1995-06-19 |
Protein Design Labs, Inc. |
Reperfusion therapy using antibodies to L-selectin
|
GB9325182D0
(en)
*
|
1993-12-08 |
1994-02-09 |
T Cell Sciences Inc |
Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions
|
ES2270425T3
(es)
*
|
1994-01-25 |
2007-04-01 |
Elan Pharmaceuticals, Inc. |
Anticuerpos humanizados contra la molecula de adhesion leucocitaria vla-4.
|
US7435802B2
(en)
|
1994-01-25 |
2008-10-14 |
Elan Pharaceuticals, Inc. |
Humanized anti-VLA4 immunoglobulins
|
US5840299A
(en)
*
|
1994-01-25 |
1998-11-24 |
Athena Neurosciences, Inc. |
Humanized antibodies against leukocyte adhesion molecule VLA-4
|
US6204007B1
(en)
|
1994-03-29 |
2001-03-20 |
Celltech Therapeutics Limited |
Antibodies against E-selectin
|
US5635597A
(en)
*
|
1994-05-27 |
1997-06-03 |
Affymax Technologies, N.V. |
Peptides that bind IL-2 receptors
|
US5622701A
(en)
*
|
1994-06-14 |
1997-04-22 |
Protein Design Labs, Inc. |
Cross-reacting monoclonal antibodies specific for E- and P-selectin
|
USRE39548E1
(en)
*
|
1994-06-17 |
2007-04-03 |
Celltech R&D Limited |
Interleukin-5 specific recombinant antibodies
|
GB9412230D0
(en)
|
1994-06-17 |
1994-08-10 |
Celltech Ltd |
Interleukin-5 specific recombiant antibodies
|
US6048972A
(en)
*
|
1994-07-13 |
2000-04-11 |
Chugai Pharmaceutical Co., Ltd. |
Recombinant materials for producing humanized anti-IL-8 antibodies
|
DE4425115A1
(de)
*
|
1994-07-15 |
1996-01-18 |
Boehringer Mannheim Gmbh |
Verfahren zur Modifizierung der Stabilität von Antikörpern
|
EP0696455A1
(en)
*
|
1994-08-11 |
1996-02-14 |
Cellena (Cell Engineering) A.G. |
Transferrin compositions to alleviate the side effects of cytotoxic drugs
|
US8771694B2
(en)
*
|
1994-08-12 |
2014-07-08 |
Immunomedics, Inc. |
Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells
|
US5707621A
(en)
*
|
1994-08-31 |
1998-01-13 |
Chugai Pharmaceutical Co., Ltd. |
Supression of nephritis-induced protein excretion by anti-IL-8
|
US6309636B1
(en)
*
|
1995-09-14 |
2001-10-30 |
Cancer Research Institute Of Contra Costa |
Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
|
US5683892A
(en)
*
|
1994-12-23 |
1997-11-04 |
Smithkline Beecham Corporation |
DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
|
US6113898A
(en)
|
1995-06-07 |
2000-09-05 |
Idec Pharmaceuticals Corporation |
Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
|
US7153508B2
(en)
|
1995-06-07 |
2006-12-26 |
Biogen Idec Inc. |
Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
|
US5811524A
(en)
*
|
1995-06-07 |
1998-09-22 |
Idec Pharmaceuticals Corporation |
Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
|
WO1996040249A1
(en)
*
|
1995-06-07 |
1996-12-19 |
Sloan-Kettering Institute For Cancer Research |
Therapeutic uses of ta99
|
US7175847B1
(en)
|
1995-06-07 |
2007-02-13 |
Biogen Idec Inc. |
Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
|
US6440418B1
(en)
|
1995-11-07 |
2002-08-27 |
Idec Pharmaceuticals Corporation |
Methods of treating autoimmune diseases with gp39-specific antibodies
|
US6001358A
(en)
*
|
1995-11-07 |
1999-12-14 |
Idec Pharmaceuticals Corporation |
Humanized antibodies to human gp39, compositions containing thereof
|
GB9600660D0
(en)
|
1996-01-12 |
1996-03-13 |
Ciba Geigy Ag |
Protein
|
WO1997033617A1
(en)
*
|
1996-03-13 |
1997-09-18 |
Protein Design Labs, Inc. |
Fas ligand fusion proteins and their uses
|
US5882644A
(en)
*
|
1996-03-22 |
1999-03-16 |
Protein Design Labs, Inc. |
Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
|
US6713305B1
(en)
|
1996-04-29 |
2004-03-30 |
Novartis Ag |
Metastasis-associated antigen and antibodies thereto
|
ATE248192T1
(de)
|
1996-06-07 |
2003-09-15 |
Neorx Corp |
HUMANISIERTE ANTIKÖRPER DIE AN DAS GLEICHE ANTIGEN WIE ANTIKÖRPER NR-LU-13 BINDEN UND DEREN VERWENDUNG IN ßPRETARGETINGß VERFAHREN
|
US6534311B2
(en)
|
1996-07-24 |
2003-03-18 |
Novartis Ag |
Drosophila melanogaster p70S6 kinase
|
US6833255B1
(en)
|
1996-07-24 |
2004-12-21 |
Novartis, Ag |
Drosophila melanogaster p70 S6 kinase
|
US7147851B1
(en)
|
1996-08-15 |
2006-12-12 |
Millennium Pharmaceuticals, Inc. |
Humanized immunoglobulin reactive with α4β7 integrin
|
EP1642908A2
(en)
*
|
1996-09-02 |
2006-04-05 |
Okumura, Ko |
Apoptosis-induced site from fas ligand
|
US6013256A
(en)
*
|
1996-09-24 |
2000-01-11 |
Protein Design Labs, Inc. |
Method of preventing acute rejection following solid organ transplantation
|
AU744146B2
(en)
*
|
1996-09-26 |
2002-02-14 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody against human parathormone related peptides
|
UA76934C2
(en)
|
1996-10-04 |
2006-10-16 |
Chugai Pharmaceutical Co Ltd |
Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
|
US7883872B2
(en)
|
1996-10-10 |
2011-02-08 |
Dyadic International (Usa), Inc. |
Construction of highly efficient cellulase compositions for enzymatic hydrolysis of cellulose
|
US20020160005A1
(en)
|
1996-11-15 |
2002-10-31 |
Trustees Of Tufts College |
Human neutralizing antibodies against hemolytic urmec syndrome
|
US7910096B2
(en)
|
1996-11-15 |
2011-03-22 |
Trustees Of Tufts College |
Human neutralizing antibodies against hemolytic uremic syndrome
|
AU713471C
(en)
|
1996-12-23 |
2002-04-18 |
Immunex Corporation |
Ligand for receptor activator of NF-kappa B, ligand is member of TNF superfamily
|
US6262238B1
(en)
*
|
1997-01-14 |
2001-07-17 |
Roche Diagnostic, Gmbh |
Process for modifying the stability of antibodies
|
US6596850B1
(en)
|
1998-01-30 |
2003-07-22 |
Ixsys, Incorporated |
Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same
|
US6590079B2
(en)
|
1997-01-30 |
2003-07-08 |
Ixsys, Incorporated |
Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
|
US20060235209A9
(en)
|
1997-03-10 |
2006-10-19 |
Jin-An Jiao |
Use of anti-tissue factor antibodies for treating thromboses
|
US7749498B2
(en)
|
1997-03-10 |
2010-07-06 |
Genentech, Inc. |
Antibodies for inhibiting blood coagulation and methods of use thereof
|
US5986065A
(en)
|
1997-03-10 |
1999-11-16 |
Sunol Molecular Corporation |
Antibodies for inhibiting blood coagulation and methods of use thereof
|
US20030109680A1
(en)
|
2001-11-21 |
2003-06-12 |
Sunol Molecular Corporation |
Antibodies for inhibiting blood coagulation and methods of use thereof
|
ZA982371B
(en)
*
|
1997-03-21 |
1998-09-28 |
Sankyo Co |
Humanized anti-human fas antibody
|
US6972323B1
(en)
|
1997-04-01 |
2005-12-06 |
Sankyo Company, Limited |
Anti-Fas antibodies
|
US6884879B1
(en)
|
1997-04-07 |
2005-04-26 |
Genentech, Inc. |
Anti-VEGF antibodies
|
US20070059302A1
(en)
|
1997-04-07 |
2007-03-15 |
Genentech, Inc. |
Anti-vegf antibodies
|
US20020032315A1
(en)
|
1997-08-06 |
2002-03-14 |
Manuel Baca |
Anti-vegf antibodies
|
SI1325932T1
(es)
|
1997-04-07 |
2005-08-31 |
Genentech Inc |
|
IL132896A0
(en)
|
1997-05-15 |
2001-03-19 |
Chugai Pharmaceutical Co Ltd |
Cachexia remedy
|
GB2339430A
(en)
*
|
1997-05-21 |
2000-01-26 |
Biovation Ltd |
Method for the production of non-immunogenic proteins
|
JP4891477B2
(ja)
|
1997-10-02 |
2012-03-07 |
マックス−プランク−ゲゼルシャフト ツール フォーデルング デル ヴィッセンシャフテン エー.ヴェー. |
血管新生及び/または既存細動脈網から側枝動脈及び/または他の動脈の発達の調節に関する方法
|
DE69838454T2
(de)
*
|
1997-10-03 |
2008-02-07 |
Chugai Seiyaku K.K. |
Natürlicher menschlicher antikörper
|
US7179892B2
(en)
|
2000-12-06 |
2007-02-20 |
Neuralab Limited |
Humanized antibodies that recognize beta amyloid peptide
|
US20080050367A1
(en)
|
1998-04-07 |
2008-02-28 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
US7964192B1
(en)
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
TWI239847B
(en)
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
EP1745799B1
(en)
|
1998-03-04 |
2015-09-02 |
The Trustees of The University of Pennsylvania |
Compositions and methods of treating tumors
|
TR200002885T2
(tr)
|
1998-04-03 |
2000-12-21 |
Chugai Seiyaku Kabushiki Kaisha |
İnsan doku faktörüne (TF) karşı insanlaştırılmış antikor
|
CA2340091C
(en)
|
1998-08-11 |
2013-02-05 |
Idec Pharmaceuticals Corporation |
Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
|
JP4689781B2
(ja)
*
|
1998-09-03 |
2011-05-25 |
独立行政法人科学技術振興機構 |
アミノ酸輸送蛋白及びその遺伝子
|
EA004270B1
(ru)
|
1998-09-14 |
2004-02-26 |
Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем |
Способы лечения множественной миеломы и индуцированной миеломой резорбции костей с помощью антагонистов интегрина
|
CN1230546C
(zh)
|
1998-10-06 |
2005-12-07 |
马克·阿龙·埃马尔法尔布 |
丝状真菌宿主领域的转化系统
|
DE69839740D1
(de)
|
1998-10-22 |
2008-08-28 |
Univ Montana |
Vakzine enthaltend Omp85 Proteine von Neisseria gonorrhoeae und Neisseria meningitidis
|
MXPA01004648A
(es)
|
1998-11-09 |
2002-05-06 |
Idec Pharma Corp |
Tratamientro de enfermedades hematologicas malignas asociadas con celulas tumorales de la circulacion usando el anticuerpo quimerico anti-cd20.
|
GB9825632D0
(en)
|
1998-11-23 |
1999-01-13 |
Novartis Ag |
Organic compounds
|
US20030035798A1
(en)
|
2000-08-16 |
2003-02-20 |
Fang Fang |
Humanized antibodies
|
CA2327260A1
(en)
|
1999-03-03 |
2000-09-08 |
Biogen, Inc. |
Methods of modulating lipid metabolism and storage
|
GB9906380D0
(en)
*
|
1999-03-19 |
1999-05-12 |
Melvin William T |
Monoclonal antibodies specific for cypibi
|
ATE298249T1
(de)
|
1999-04-22 |
2005-07-15 |
Biogen Idec Inc |
Verfahren zur behandlung einer fibrose unter verwendung eines antagonisten der integrin alpha- 4 untereinheit
|
IT1306704B1
(it)
*
|
1999-05-26 |
2001-10-02 |
Sirs Societa Italiana Per La R |
Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
|
MXPA01012388A
(es)
|
1999-06-01 |
2002-07-30 |
Biogen Inc |
Anticuerpo monoclonal bloqueador para vla-1 y su uso para el tratamiento de trastornos inflamatorios.
|
UA81216C2
(en)
|
1999-06-01 |
2007-12-25 |
|
Prevention and treatment of amyloid disease
|
US7144991B2
(en)
|
1999-06-07 |
2006-12-05 |
Aletheon Pharmaceuticals, Inc. |
Streptavidin expressed gene fusions and methods of use thereof
|
US6531580B1
(en)
|
1999-06-24 |
2003-03-11 |
Ixsys, Inc. |
Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same
|
TWI255718B
(en)
|
1999-07-02 |
2006-06-01 |
Chugai Pharmaceutical Co Ltd |
Ameliorative agent for low vasopressin concentration
|
US8557244B1
(en)
|
1999-08-11 |
2013-10-15 |
Biogen Idec Inc. |
Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
|
ES2301491T3
(es)
*
|
1999-09-30 |
2008-07-01 |
Kyowa Hakko Kogyo Co., Ltd. |
Anticuerpo humano de trasplante con region de determinacion de la complementariedad contra gangliosido gd3 y derivados del anticuerpo contra gangliosido gd3.
|
US6849425B1
(en)
|
1999-10-14 |
2005-02-01 |
Ixsys, Inc. |
Methods of optimizing antibody variable region binding affinity
|
ES2629683T3
(es)
|
1999-11-30 |
2017-08-14 |
Mayo Foundation For Medical Education And Research |
B7-H1, una nueva molécula inmunorreguladora
|
EP2332578A1
(en)
|
1999-12-16 |
2011-06-15 |
Biogen Idec MA Inc. |
Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists
|
DE60142614D1
(de)
|
2000-01-27 |
2010-09-02 |
Medimmune Inc |
Inität
|
ATE373719T1
(de)
*
|
2000-02-03 |
2007-10-15 |
Millennium Pharm Inc |
Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
|
WO2001058949A2
(en)
|
2000-02-11 |
2001-08-16 |
Biogen, Inc. |
Heterologous polypeptide of the tnf family
|
CZ2008595A3
(cs)
|
2000-02-24 |
2017-05-03 |
Washington University |
Léčivo pro prevenci nebo léčení preklinické nebo klinické Alzheimerovy nemoci
|
ES2390761T3
(es)
|
2000-03-01 |
2012-11-16 |
Medimmune, Llc |
Anticuerpos recombinantes de alta potencia y método para producción de los mismos
|
AU4574501A
(en)
|
2000-03-17 |
2001-10-03 |
Millennium Pharm Inc |
Method of inhibiting stenosis and restenosis
|
US20010046496A1
(en)
|
2000-04-14 |
2001-11-29 |
Brettman Lee R. |
Method of administering an antibody
|
US7030219B2
(en)
|
2000-04-28 |
2006-04-18 |
Johns Hopkins University |
B7-DC, Dendritic cell co-stimulatory molecules
|
WO2001082968A1
(fr)
|
2000-04-28 |
2001-11-08 |
Chugai Seiyaku Kabushiki Kaisha |
Inhibiteurs de proliferation cellulaire
|
AU2001261103B2
(en)
|
2000-04-29 |
2007-08-23 |
University Of Iowa Research Foundation |
Diagnostics and therapeutics for macular degeneration-related disorders
|
US7476383B2
(en)
|
2000-05-02 |
2009-01-13 |
The Uab Research Foundation |
Antibody selective for DR4 and uses thereof
|
US7279160B2
(en)
|
2000-05-02 |
2007-10-09 |
The Uab Research Foundation |
Combinations of DR5 antibodies and other therapeutic agents
|
TWI318983B
(en)
|
2000-05-02 |
2010-01-01 |
Uab Research Foundation |
An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
|
GB0013810D0
(en)
|
2000-06-06 |
2000-07-26 |
Celltech Chiroscience Ltd |
Biological products
|
GB0020685D0
(en)
|
2000-08-22 |
2000-10-11 |
Novartis Ag |
Organic compounds
|
DE60143535D1
(de)
|
2000-10-02 |
2011-01-05 |
Novartis Vaccines & Diagnostic |
Humane antikörper gegen cd40
|
US6989247B2
(en)
|
2000-11-28 |
2006-01-24 |
Celltech R & D, Inc. |
Compositions and methods for diagnosing or treating psoriasis
|
US7179900B2
(en)
|
2000-11-28 |
2007-02-20 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
PE20020574A1
(es)
|
2000-12-06 |
2002-07-02 |
Wyeth Corp |
Anticuerpos humanizados que reconocen el peptido amiloideo beta
|
CZ20032672A3
(cs)
*
|
2001-04-06 |
2003-12-17 |
University Of Bristol |
CD25 vazebná molekula pro použití při prevenci nebo léčení některých nemocí u pacientů rezistentních na léčbu steroidy
|
CZ303450B6
(cs)
|
2001-04-13 |
2012-09-19 |
Biogen Idec Ma Inc. |
Protilátky k VLA-1, kompozice je obsahující a nukleové kyseliny, které je kódují, zpusob stanovení hladiny VLA-1 a použití pri lécení imunologického onemocnení
|
US6972324B2
(en)
|
2001-05-18 |
2005-12-06 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Antibodies specific for CD44v6
|
EE200300569A
(et)
*
|
2001-05-18 |
2004-04-15 |
Boehringer Ingelheim International Gmbh |
CD44v6-spetsiifilised antikehad
|
US7541443B2
(en)
*
|
2001-06-14 |
2009-06-02 |
Tolerrx, Inc. |
Anti-CD4 antibodies
|
JP2005500034A
(ja)
|
2001-06-20 |
2005-01-06 |
プロション バイオテク リミテッド |
受容体型タンパク質チロシンキナーゼ活性化を遮断する抗体、そのスクリーニング方法、及びその使用
|
US20030013081A1
(en)
|
2001-06-26 |
2003-01-16 |
Olson William C. |
Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection
|
JP4675512B2
(ja)
*
|
2001-07-10 |
2011-04-27 |
三井化学株式会社 |
熱殺菌方法
|
CA2454358A1
(en)
|
2001-07-19 |
2003-07-31 |
Perlan Therapeutics, Inc. |
Multimeric proteins and methods of making and using same
|
EP1420032B2
(en)
†
|
2001-08-03 |
2015-12-16 |
Medical & Biological Laboratories Co., Ltd. |
Antibody recognizing gm1 ganglioside-bound amyloid beta-protein and dna encoding the antibody
|
EP1944040B1
(en)
|
2001-08-17 |
2012-08-01 |
Washington University |
Assay method for Alzheimer's disease
|
WO2003035887A1
(en)
|
2001-09-20 |
2003-05-01 |
Immunex Corporation |
Selection of cells expressing heteromeric polypeptides
|
NZ531818A
(en)
|
2001-09-25 |
2005-10-28 |
Fujisawa Pharmaceutical Co |
Recombinant anti-osteopontin antibody and use in the treatment of autoimmune diseases such as rheumatoid arthritis and osteoarthritis
|
GB0124317D0
(en)
|
2001-10-10 |
2001-11-28 |
Celltech R&D Ltd |
Biological products
|
US20030190705A1
(en)
*
|
2001-10-29 |
2003-10-09 |
Sunol Molecular Corporation |
Method of humanizing immune system molecules
|
HUP0402333A3
(en)
*
|
2001-11-12 |
2007-05-02 |
Merck Patent Gmbh |
Modified anti-tnf alpha antibody
|
EP1944043A1
(en)
|
2001-11-21 |
2008-07-16 |
The Trustees of the University of Pennsylvania |
Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
|
HU230364B1
(hu)
|
2001-11-21 |
2016-03-29 |
The Trustees Of The University Of Pennsylvania |
Simian adenovírus nukleinsav és aminosav-szekvencia, azt tartalmazó vektorok, és eljárások annak alkalmazására
|
EP2298717B1
(en)
|
2001-11-30 |
2015-10-28 |
Biogen MA Inc. |
Antibodies against monocyte chemotactic proteins
|
US7393648B2
(en)
|
2001-12-03 |
2008-07-01 |
Alexion Pharmaceuticals, Inc. |
Hybrid antibodies
|
EP2298817A1
(en)
|
2001-12-03 |
2011-03-23 |
Alexion Pharmaceuticals, Inc. |
Hybrid antibodies
|
GB0129105D0
(en)
|
2001-12-05 |
2002-01-23 |
Celltech R&D Ltd |
Expression control using variable intergenic sequences
|
AU2003208415B2
(en)
*
|
2002-02-14 |
2009-05-28 |
Immunomedics, Inc. |
Anti-CD20 antibodies and fusion proteins thereof and methods of use
|
JP2006508631A
(ja)
*
|
2002-02-22 |
2006-03-16 |
プロジェニクス・ファーマスーティカルズ・インコーポレイテッド |
抗ccr5抗体
|
NZ579583A
(en)
|
2002-02-25 |
2011-04-29 |
Elan Pharm Inc |
Administration of agents that bind to an alpha-4 integrin for the treatment of inflammation
|
MY139983A
(en)
|
2002-03-12 |
2009-11-30 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
CN102659946A
(zh)
|
2002-03-13 |
2012-09-12 |
拜奥根Idec马萨诸塞公司 |
抗αvβ6抗体
|
US20060171940A1
(en)
|
2002-03-20 |
2006-08-03 |
Celltech R&D Limited |
Antibody disulfide isomers, use thereof, and methods of analyzing same
|
WO2003080675A2
(en)
*
|
2002-03-22 |
2003-10-02 |
Amrad Operations Pty Ltd |
MONOCLONAL ANTIBODY AGAINST INTERLEUKIN-13 RECEPTOR ALPHA 1 (IL-13Rα1)
|
GB0210121D0
(en)
|
2002-05-02 |
2002-06-12 |
Celltech R&D Ltd |
Biological products
|
US7202067B2
(en)
|
2002-05-14 |
2007-04-10 |
Martek Biosciences Corporation |
Carotene synthase gene and uses therefor
|
ATE518885T1
(de)
|
2002-05-28 |
2011-08-15 |
Ucb Pharma Sa |
Peg-positionsisomer von einem antikorper gegen tnfalpha (cdp870)
|
US7351803B2
(en)
*
|
2002-05-30 |
2008-04-01 |
Macrogenics, Inc. |
CD16A binding proteins and use for the treatment of immune disorders
|
US7132100B2
(en)
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
GB0213745D0
(en)
|
2002-06-14 |
2002-07-24 |
Univ Edinburgh |
Enzyme
|
AU2002319236A1
(en)
|
2002-06-14 |
2003-12-31 |
Monier Tadros |
Method for the production of protamine
|
CA2490804C
(en)
*
|
2002-06-28 |
2016-12-06 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Method of treating autoimmune diseases with interferon-beta and il-2r antagonist
|
WO2010011999A2
(en)
|
2008-07-25 |
2010-01-28 |
The Regents Of The University Of California |
Methods and compositions for eliciting an amyloid-selective immune response
|
US7432351B1
(en)
|
2002-10-04 |
2008-10-07 |
Mayo Foundation For Medical Education And Research |
B7-H1 variants
|
GB0228832D0
(en)
|
2002-12-10 |
2003-01-15 |
Novartis Ag |
Organic compound
|
US8506959B2
(en)
|
2002-11-01 |
2013-08-13 |
Neotope Biosciences Limited |
Prevention and treatment of synucleinopathic and amyloidogenic disease
|
TW200509968A
(en)
|
2002-11-01 |
2005-03-16 |
Elan Pharm Inc |
Prevention and treatment of synucleinopathic disease
|
JP4966497B2
(ja)
|
2002-11-15 |
2012-07-04 |
ゲンマブ エー/エス |
Cd25に対するヒトモノクローナル抗体
|
CA2537263C
(en)
|
2002-11-27 |
2017-05-30 |
Minerva Biotechnologies Corporation |
Techniques and compositions for the diagnosis and treatment of cancer (muc1)
|
EP3263596A1
(en)
|
2002-12-16 |
2018-01-03 |
Genentech, Inc. |
Immunoglobulin variants and uses thereof
|
AU2004205684A1
(en)
|
2003-01-23 |
2004-08-05 |
Genentech, Inc. |
Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
|
PE20040942A1
(es)
|
2003-01-24 |
2004-12-28 |
Elan Pharm Inc |
Preparacion y tratamiento para las enfermedades desmielinizantes y paralisis mediante la aplicacion de agentes remielinizantes
|
EP1460088A1
(en)
|
2003-03-21 |
2004-09-22 |
Biotest AG |
Humanized anti-CD4 antibody with immunosuppressive properties
|
US7321065B2
(en)
|
2003-04-18 |
2008-01-22 |
The Regents Of The University Of California |
Thyronamine derivatives and analogs and methods of use thereof
|
ES2368737T3
(es)
*
|
2003-04-23 |
2011-11-21 |
Medarex, Inc. |
Anticuerpos humanizados contra el receptor de interferon alfa 1 (ifnar-1).
|
BRPI0410495A
(pt)
|
2003-04-23 |
2006-06-13 |
Medarex Inc |
composição para o tratamento de uma doença inflamatória dos intestinos e uso de um antagonista de interferon tipo i para preparar um medicamento
|
WO2005013889A2
(en)
|
2003-05-19 |
2005-02-17 |
Elan Pharmaceuticals, Inc. |
Truncated fragments of alpha-synuclein in lewy body disease
|
US7358331B2
(en)
|
2003-05-19 |
2008-04-15 |
Elan Pharmaceuticals, Inc. |
Truncated fragments of alpha-synuclein in Lewy body disease
|
EP1639014B1
(en)
|
2003-06-13 |
2010-09-22 |
Biogen Idec MA Inc. |
Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
|
US8153410B2
(en)
|
2003-07-07 |
2012-04-10 |
Fox Chase Cancer Center |
Alternate morpheein forms of allosteric proteins as a target for the development of bioactive molecules
|
US20060162014A1
(en)
|
2003-07-07 |
2006-07-20 |
Jaffe Eileen K |
Alternate morpheeins of allosteric proteins as a target for the development of bioactive molecules
|
EP3594228A1
(en)
|
2003-07-08 |
2020-01-15 |
Genentech, Inc. |
Il-17a/f heterologous polypedtides and therapeutic uses thereof
|
ES2523837T3
(es)
|
2003-07-18 |
2014-12-01 |
Amgen Inc. |
Agentes de unión específica al factor de crecimiento de hepatocitos
|
US7834155B2
(en)
|
2003-07-21 |
2010-11-16 |
Immunogen Inc. |
CA6 antigen-specific cytotoxic conjugate and methods of using the same
|
US20060228350A1
(en)
*
|
2003-08-18 |
2006-10-12 |
Medimmune, Inc. |
Framework-shuffling of antibodies
|
GB0321997D0
(en)
|
2003-09-19 |
2003-10-22 |
Novartis Ag |
Organic compound
|
CN101133083A
(zh)
*
|
2003-11-11 |
2008-02-27 |
中外制药株式会社 |
人源化的抗cd47抗体
|
EP1687325A4
(en)
|
2003-11-12 |
2008-11-12 |
Progenics Pharm Inc |
NOVEL GLYCOPROTEIN CODING SEQUENCES OF HEPATITIS C VIRUS
|
EP2070947B1
(en)
|
2003-12-05 |
2014-06-11 |
multimmune GmbH |
Therapeutic and diagnostic anti-Hsp70 antibodies
|
CA2548813A1
(en)
|
2003-12-08 |
2005-06-23 |
Morphotek, Inc. |
Antibodies that specifically bind pms2
|
EP1699487A4
(en)
|
2003-12-15 |
2009-07-08 |
Alexion Pharma Inc |
NEW ANTI-DC-SIGN ANTIBODIES
|
ITRM20030601A1
(it)
*
|
2003-12-24 |
2005-06-25 |
Lay Line Genomics Spa |
Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
|
US20090324604A1
(en)
|
2004-01-07 |
2009-12-31 |
Chiron Corporation |
M-csf specific monoclonal antibody and uses thereof
|
US20070280950A1
(en)
|
2004-01-19 |
2007-12-06 |
Medical And Biological Laboratories Co., Ltd. |
Inflammatory Cytokine Inhibitors
|
EP1728077A4
(en)
|
2004-01-30 |
2008-11-05 |
Dana Farber Cancer Inst Inc |
METHOD FOR DETERMINING AND QUANTIFYING A RADIATION OR GENOTOXIN EXPOSURE
|
EP2340850A1
(en)
|
2004-02-10 |
2011-07-06 |
The Regents of the University of Colorado, a Body Corporate |
Inhibition of factor B, the alternative complement pathway and methods related thereto
|
TWI359026B
(en)
|
2004-02-12 |
2012-03-01 |
Sankyo Co |
Pharmaceutical composition for the osteoclast rela
|
WO2005080431A2
(en)
|
2004-02-12 |
2005-09-01 |
Morphotek, Inc. |
Monoclonal antibodies that specifically bind to folate receptor alpha
|
EP1717250A4
(en)
|
2004-02-20 |
2008-10-01 |
Immuno Biological Lab Co Ltd |
MONOCLONAL ANTIBODY AND ITS USE
|
EP1730196B1
(en)
|
2004-03-12 |
2010-12-22 |
Vasgene Therapeutics, Inc. |
Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
|
US7625549B2
(en)
|
2004-03-19 |
2009-12-01 |
Amgen Fremont Inc. |
Determining the risk of human anti-human antibodies in transgenic mice
|
US20050260679A1
(en)
|
2004-03-19 |
2005-11-24 |
Sirid-Aimee Kellerman |
Reducing the risk of human anti-human antibodies through V gene manipulation
|
MY162179A
(en)
|
2004-04-01 |
2017-05-31 |
Elan Pharm Inc |
Steroid sparing agents and methods of using same
|
CA2562038C
(en)
|
2004-04-02 |
2017-04-25 |
The Regents Of The University Of California |
Methods and compositions for treating and preventing disease associated with .alpha.v.beta.5 integrin
|
WO2005116657A2
(en)
|
2004-05-24 |
2005-12-08 |
Universität Zu Köln |
Identification of ergothioneine transporter and therapeutic uses thereof
|
EP1602926A1
(en)
|
2004-06-04 |
2005-12-07 |
University of Geneva |
Novel means and methods for the treatment of hearing loss and phantom hearing
|
KR101541658B1
(ko)
|
2004-06-21 |
2015-08-07 |
메다렉스, 엘.엘.시. |
인터페론 알파 수용체 1 항체 및 그의 용도
|
GB0414054D0
(en)
|
2004-06-23 |
2004-07-28 |
Owen Mumford Ltd |
Improvements relating to automatic injection devices
|
MX2007001015A
(es)
|
2004-07-26 |
2007-04-12 |
Biogen Idec Inc |
Anticuerpos anti-cd154.
|
GB0417487D0
(en)
|
2004-08-05 |
2004-09-08 |
Novartis Ag |
Organic compound
|
MX2007001679A
(es)
|
2004-08-09 |
2007-05-23 |
Elan Pharm Inc |
Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica.
|
CA2478458A1
(en)
|
2004-08-20 |
2006-02-20 |
Michael Panzara |
Treatment of pediatric multiple sclerosis
|
FI20041204A0
(fi)
|
2004-09-16 |
2004-09-16 |
Riikka Lund |
Menetelmät immuunivälitteisiin sairauksiin liittyvien uusien kohdegeenien hyödyntämiseksi
|
DE602005026219D1
(de)
|
2004-10-01 |
2011-03-17 |
Max Planck Gesellschaft |
Gegen das säugetier-eag1-ionenkanalprotein gerichtete antikörper
|
EP1810026B1
(en)
|
2004-10-06 |
2018-04-18 |
Mayo Foundation For Medical Education And Research |
B7-h1 and pd-1 in treatment of renal cell carcinoma
|
US7928205B2
(en)
|
2004-10-22 |
2011-04-19 |
Amgen Inc. |
Methods for refolding of recombinant antibodies
|
WO2006055178A2
(en)
|
2004-10-25 |
2006-05-26 |
Merck & Co., Inc. |
Anti-addl antibodies and uses thereof
|
AU2005306399B2
(en)
|
2004-11-19 |
2012-02-09 |
Biogen Ma Inc. |
Treatment for multiple sclerosis
|
CA2590337C
(en)
|
2004-12-15 |
2017-07-11 |
Neuralab Limited |
Humanized amyloid beta antibodies for use in improving cognition
|
ES2320374T3
(es)
|
2005-01-05 |
2009-05-21 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. |
Dominios de inmunoglobulina sintetica con propiedades de enlace modificadas en regiones de la molecula diferentes de las regiones de determinacion de complementariedad.
|
PT2682126T
(pt)
|
2005-01-27 |
2017-02-28 |
Children`S Hospital & Res Center At Oakland |
Vacinas de vesícula com base em agn1870 para proteção de amplo espetro contra doenças causadas por neisseria meningitidis
|
EP1856287B1
(en)
|
2005-02-14 |
2011-09-28 |
University of Iowa Research Foundation |
Methods and reagents for treatment and diagnosis of age-related macular degeneration
|
DK2529619T3
(en)
|
2005-02-17 |
2016-01-11 |
Biogen Ma Inc |
Treatment of neurological disorders
|
US8048992B2
(en)
|
2005-02-28 |
2011-11-01 |
Institute For Antibodies Co., Ltd. |
Anti-IgSF4 antibody and utilization of the same
|
ATE478707T1
(de)
|
2005-03-02 |
2010-09-15 |
Biogen Idec Inc |
Kim-1-antikörper zur behandlung von th2- vermittelten erkrankungen
|
ES2386367T3
(es)
|
2005-03-10 |
2012-08-17 |
Morphotek, Inc. |
Anticuerpos anti-mesotelina
|
WO2006100449A1
(en)
|
2005-03-19 |
2006-09-28 |
Medical Research Council |
Improvements in or relating to treatment and prevention of viral infections
|
DK1866339T3
(da)
|
2005-03-25 |
2013-09-02 |
Gitr Inc |
GTR-bindende molekyler og anvendelser heraf
|
EP1875244B1
(en)
|
2005-03-30 |
2019-01-23 |
Minerva Biotechnologies Corporation |
Proliferation of muc1 expressing cells
|
DK1875244T3
(en)
|
2005-03-30 |
2019-04-29 |
Minerva Biotechnologies Corp |
Proliferation of MUC1-Expressing Cells
|
ES2440953T3
(es)
|
2005-03-31 |
2014-01-31 |
The General Hospital Corporation |
Modulación de la actividad de HGF/HGFR para tratar un linfedema
|
JP2008537595A
(ja)
|
2005-04-04 |
2008-09-18 |
バイオジェン アイデック エムエイ インコーポレイテッド |
治療タンパク質に対する免疫反応を評価するための方法および生成物
|
EP2172487A1
(en)
|
2005-04-22 |
2010-04-07 |
Morphotek Inc. |
Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells
|
JP2008538700A
(ja)
|
2005-04-22 |
2008-11-06 |
モルフォテック、インク. |
免疫エフェクター活性を有するエンドシアリン細胞に内部移行する抗体
|
US20090041783A1
(en)
|
2005-04-28 |
2009-02-12 |
Mochida Pharmaceutical Co., Ltd. |
Anti-platelet membrane glycoprotein vi monoclonal antibody
|
EP1885396A2
(en)
|
2005-05-04 |
2008-02-13 |
Quark Pharmaceuticals, Inc. |
Recombinant antibodies against cd55 and cd59 and uses thereof
|
HUE029214T2
(en)
|
2005-05-10 |
2017-02-28 |
Incyte Holdings Corp |
Indolamine-2,3-dioxygenase modulators and methods for their use
|
CA2609038A1
(en)
|
2005-05-18 |
2006-11-23 |
Trinity Biosystems, Inc. |
Methods and compositions for immunizing against chlamydia infection
|
AU2006247039B2
(en)
|
2005-05-19 |
2011-03-03 |
Amgen Inc. |
Compositions and methods for increasing the stability of antibodies
|
JP5707024B2
(ja)
|
2005-05-26 |
2015-04-22 |
ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレイトTHE REGENTS OF THE UNIVERSITY OF COLORADO,a body corporate |
外傷性脳損傷、脊髄損傷および関連状態を治療するために補体副経路を阻害する作用剤
|
CN102441163A
(zh)
|
2005-05-27 |
2012-05-09 |
比奥根艾迪克Ma公司 |
结合tweak的抗体
|
EP2364998A1
(en)
|
2005-06-16 |
2011-09-14 |
The Feinstein Institute for Medical Research |
Antibodies against HMGB1 and fragments thereof
|
EP2937360A1
(en)
|
2005-06-17 |
2015-10-28 |
Merck Sharp & Dohme Corp. |
Ilt3 binding molecules and uses therefor
|
KR101502920B1
(ko)
*
|
2005-06-21 |
2015-03-17 |
조마 (유에스) 엘엘씨 |
IL-1β 결합성 항체 및 그의 단편
|
CN104072614B
(zh)
|
2005-07-08 |
2017-04-26 |
生物基因Ma公司 |
抗-αvβ6 抗体及其用途
|
FR2888850B1
(fr)
|
2005-07-22 |
2013-01-11 |
Pf Medicament |
Nouveaux anticorps anti-igf-ir et leurs applications
|
JP2009514790A
(ja)
|
2005-07-22 |
2009-04-09 |
プロジェニクス・ファーマスーティカルズ・インコーポレイテッド |
Hiv−1−感染患者におけるウイルス負荷を減少させる方法
|
WO2007016285A2
(en)
|
2005-07-28 |
2007-02-08 |
Novartis Ag |
M-csf specific monoclonal antibody and uses thereof
|
WO2007030560A2
(en)
|
2005-09-08 |
2007-03-15 |
Philadelphia Health & Education Corporation, D/B/A Drexel University College Of Medicine |
Identification of modulators of serine protease inhibitor kazal and their use as anti-cancer and anti-viral agents
|
CA2623197A1
(en)
|
2005-09-22 |
2007-03-29 |
Prosci Incorporated |
Glycosylated polypeptides produced in yeast mutants and methods of use thereof
|
WO2007051077A2
(en)
|
2005-10-28 |
2007-05-03 |
The Regents Of The University Of California |
Methods and compounds for lymphoma cell detection and isolation
|
WO2007049770A1
(ja)
|
2005-10-28 |
2007-05-03 |
Meiji Seika Kaisha, Ltd. |
緑膿菌の外膜タンパク質pa5158
|
RS53055B
(en)
|
2005-11-01 |
2014-04-30 |
Abbvie Biotechnology Ltd |
PROCEDURES FOR DETERMINING THE EFFICIENCY OF ADALIMUMAB IN RESPONDENTS WHO HAVE ANKILLOSATIVE SPONDILITIS USING CTX-II AND MMP3 AS BIOMARKERS
|
CA2627446A1
(en)
|
2005-11-21 |
2007-05-31 |
Laboratoires Serono S.A. |
Compositions and methods of producing hybrid antigen binding molecules and uses thereof
|
JP5486808B2
(ja)
|
2005-11-30 |
2014-05-07 |
アッヴィ・インコーポレイテッド |
アミロイドベータタンパク質に対するモノクローナル抗体及びその使用
|
DOP2006000277A
(es)
|
2005-12-12 |
2007-08-31 |
Bayer Pharmaceuticals Corp |
Anticuerpos anti mn y métodos para su utilización
|
WO2007084599A2
(en)
|
2006-01-18 |
2007-07-26 |
The General Hospital Corporation |
Methods of increasing lymphatic function
|
US20080317710A1
(en)
|
2006-02-22 |
2008-12-25 |
University Of Zurich |
Methods For Treating Autoimmune or Demyelinating Diseases
|
AU2007226627B2
(en)
|
2006-03-10 |
2012-09-20 |
Zymogenetics, Inc. |
Antibodies that bind both IL-17A and IL-17F and methods of using the same
|
US9315578B2
(en)
|
2006-03-23 |
2016-04-19 |
Tohoku Univeristy |
High functional bispecific antibody
|
CN101454446A
(zh)
|
2006-03-30 |
2009-06-10 |
明治制果株式会社 |
绿脓杆菌的外膜蛋白pa0427
|
EP2738179A1
(en)
|
2006-04-05 |
2014-06-04 |
AbbVie Biotechnology Ltd |
Antibody purification
|
EP2666479A3
(en)
|
2006-04-10 |
2014-03-26 |
Abbott Biotechnology Ltd |
Uses and compositions for treatment of juvenile rheumatoid arthritis
|
CA2564435A1
(en)
|
2006-04-10 |
2007-10-10 |
Abbott Biotechnology Ltd. |
Methods for monitoring and treating intestinal disorders
|
WO2008063213A2
(en)
|
2006-04-10 |
2008-05-29 |
Abbott Biotechnology Ltd. |
Uses and compositions for treatment of psoriatic arthritis
|
JP5496658B2
(ja)
|
2006-05-25 |
2014-05-21 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
脳卒中を処置する方法
|
RU2429016C2
(ru)
|
2006-05-31 |
2011-09-20 |
Астеллас Фарма Инк. |
Гуманизированное антитело против остеопонтина человека
|
WO2008042024A2
(en)
|
2006-06-01 |
2008-04-10 |
Elan Pharmaceuticals, Inc. |
Neuroactive fragments of app
|
CA2655504A1
(en)
|
2006-06-15 |
2007-12-21 |
Fibron Ltd. |
Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
|
JP5597793B2
(ja)
|
2006-06-19 |
2014-10-01 |
メルク・シャープ・アンド・ドーム・コーポレーション |
Ilt3結合分子およびその使用
|
CA2651992A1
(en)
|
2006-06-30 |
2008-01-10 |
Abbott Biotechnology Ltd. |
Automatic injection device
|
AT503889B1
(de)
|
2006-07-05 |
2011-12-15 |
Star Biotechnologische Forschungs Und Entwicklungsges M B H F |
Multivalente immunglobuline
|
EP2292644A3
(en)
|
2006-07-07 |
2011-05-25 |
Intercell AG |
Small Streptococcus pyogenes antigens and their use
|
EA200970108A1
(ru)
|
2006-07-10 |
2009-12-30 |
Байоджен Айдек Ма Инк. |
Композиции и способы для ингибирования роста smad4-дефицитных форм рака
|
WO2008007648A1
(fr)
|
2006-07-10 |
2008-01-17 |
Institute For Antibodies Co., Ltd. |
Procédé de classification d'antigène, procédé d'identification d'antigène, procédé d'obtention d' un ensemble d'antigènes ou d'anticorps, procédés de construction d'un panel d'anticorps, anticorps et ens
|
CN101626783A
(zh)
|
2006-08-04 |
2010-01-13 |
诺华有限公司 |
Ephb3-特异性抗体和其应用
|
JP2010502573A
(ja)
|
2006-08-11 |
2010-01-28 |
ユニヴァーシティ オブ メディスン アンド デンティストリー オブ ニュー ジャージー |
二重増感剤含有ルミネッセンス化合物および結合体、ならびにその使用
|
BRPI0715718A2
(pt)
|
2006-08-18 |
2014-06-24 |
Novartis Ag |
Anticorpo, métodos de triar para um anticorpo para o domínio extracelular de uma proteína prlr, de alterar sistematicamente anticorpos e triar para um anticorpo para o domínio extracelular de uma proteína prlr, de tratar um indivíduo que sofre de câncer, de alvejar uma célula tumoral que expressa prlr, de usar uma célula hospedeira, de identificar um indivíduo com necessidade de tratamento com um anticorpo anti-prlr, e de monitorar terapia de câncer em um indivíduo, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, composição farmacêutica, e, kit
|
EP2500416A1
(en)
|
2006-09-13 |
2012-09-19 |
Abbott Laboratories |
Cell culture improvements
|
NZ597334A
(en)
|
2006-09-13 |
2014-02-28 |
Abbott Lab |
Cell culture improvements
|
JPWO2008032833A1
(ja)
|
2006-09-14 |
2010-01-28 |
株式会社医学生物学研究所 |
Adcc活性を増強させた抗体及びその製造方法
|
FR2906533B1
(fr)
|
2006-09-28 |
2013-02-22 |
Pf Medicament |
Procede de generation d'anticorps actifs contre un antigene de resistance,anticorps obtenus par ledit procede et leurs utilisations
|
EP2094733A1
(en)
|
2006-11-03 |
2009-09-02 |
U3 Pharma GmbH |
Fgfr4 antibodies
|
CA2669731C
(en)
|
2006-11-10 |
2016-01-19 |
Livtech Inc. |
Anti-human dlk-1 antibody showing anti-tumor activity in vivo
|
BRPI0718406A2
(pt)
|
2006-11-17 |
2013-12-17 |
Novartis Ag |
Moléculas de ligação de lingo e uso farmacêutico das mesmas
|
EP1923069A1
(en)
|
2006-11-20 |
2008-05-21 |
Intercell AG |
Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto
|
US8288110B2
(en)
|
2006-12-04 |
2012-10-16 |
Perkinelmer Health Sciences, Inc. |
Biomarkers for detecting cancer
|
WO2008070780A1
(en)
|
2006-12-07 |
2008-06-12 |
Novartis Ag |
Antagonist antibodies against ephb3
|
WO2008073914A2
(en)
|
2006-12-10 |
2008-06-19 |
Dyadic International Inc. |
Expression and high-throughput screening of complex expressed dna libraries in filamentous fungi
|
WO2008083169A2
(en)
|
2006-12-26 |
2008-07-10 |
The Johns Hopkins University |
Compositions and methods for the treatment of immunologic disorders
|
US7989173B2
(en)
|
2006-12-27 |
2011-08-02 |
The Johns Hopkins University |
Detection and diagnosis of inflammatory disorders
|
JP5481199B2
(ja)
|
2006-12-27 |
2014-04-23 |
ザ ジョンズ ホプキンス ユニバーシティー |
炎症および自己免疫疾患を治療するための組成物および方法
|
EP2118309B1
(en)
|
2006-12-29 |
2015-01-28 |
The Regents of the University of Colorado, a body corporate |
Diagnostic and therapeutic target for autoimmune diseases and uses thereof
|
SI2099826T1
(sl)
|
2007-01-05 |
2014-02-28 |
University Of Zurich Prorektorat Forschung |
Anti-beta-amiloidno protitelo in njegova uporaba
|
CA2675379A1
(en)
|
2007-01-12 |
2008-07-17 |
Intercell Ag |
Protective proteins of s. agalactiae, combinations thereof and methods of using the same
|
EP2114983B8
(en)
|
2007-02-07 |
2015-02-18 |
The Regents of the University of Colorado, A Body Corporate |
Axl tyrosine kinase inhibitors and methods of making and using the same
|
RS55636B1
(sr)
|
2007-02-16 |
2017-06-30 |
Genzyme Corp |
Metode za prepoznavanje rizika od poremećaja štitne žlezde
|
HUE028731T2
(en)
|
2007-02-23 |
2016-12-28 |
Prothena Biosciences Ltd |
Prevention and treatment of synucleinopathic and amyloidogenic diseases
|
EP2124988B1
(en)
|
2007-02-23 |
2014-11-12 |
The Trustees of Columbia University in the City of New York |
Methods to activate or block the hla-e/qa-1 restricted cd8+ t cell regulatory pathway to treat immunological disease
|
DK3067066T3
(da)
|
2007-02-23 |
2019-05-20 |
Prothena Biosciences Ltd |
Forebyggelse og behandling af synukleinopatisk og amyloidogenisk sygdom
|
BRPI0808940B8
(pt)
|
2007-03-13 |
2021-05-25 |
Univ Zuerich Univ Of Zurich |
anticorpo humano-murino quimérico ou xegogeneico, humanizado, humano ou seu fragmento de ligação, vetor de expressão, microrganismo transgênico, método para preparar um anticorpo ou um fragmento de ligação, composição, composição de diagnóstico, uso do anticorpo ou fragmento de ligação, kit para o diagnóstico de um tumor e uso da molécula de antígeno ligante ao tumor
|
PL2125894T3
(pl)
|
2007-03-22 |
2019-08-30 |
Biogen Ma Inc. |
Białka wiążące, w tym przeciwciała, pochodne przeciwciał i fragmenty przeciwciał, które swoiście wiążą się z CD154 i ich zastosowania
|
HUE031269T2
(en)
|
2007-04-05 |
2017-06-28 |
Morphotek Inc |
Methods for inhibiting the binding of endosial ligands
|
WO2008134659A2
(en)
|
2007-04-27 |
2008-11-06 |
Zymogenetics, Inc. |
Antagonists to il-17a, il-17f, and il-23p19 and methods of use
|
EP2360177A1
(en)
|
2007-05-02 |
2011-08-24 |
Intercell AG |
Klebsiella antigens
|
WO2008143797A1
(en)
|
2007-05-11 |
2008-11-27 |
Genzyme Corporation |
Methods of producing a secreted protein
|
US7709215B2
(en)
|
2007-06-01 |
2010-05-04 |
Cytonics Corporation |
Method for diagnosing and treating acute joint injury
|
EP1997830A1
(en)
|
2007-06-01 |
2008-12-03 |
AIMM Therapeutics B.V. |
RSV specific binding molecules and means for producing them
|
WO2008154543A2
(en)
|
2007-06-11 |
2008-12-18 |
Abbott Biotechnology Ltd. |
Methods for treating juvenile idiopathic arthritis
|
US8048420B2
(en)
|
2007-06-12 |
2011-11-01 |
Ac Immune S.A. |
Monoclonal antibody
|
US8613923B2
(en)
|
2007-06-12 |
2013-12-24 |
Ac Immune S.A. |
Monoclonal antibody
|
EP2170390B1
(en)
|
2007-06-14 |
2018-11-07 |
Biogen MA Inc. |
Natalizumab antibody formulations
|
EP2511291A3
(en)
|
2007-06-18 |
2012-11-07 |
Intercell AG |
Chlamydia antigens
|
ES2627223T3
(es)
|
2007-06-26 |
2017-07-27 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H |
Presentación de agentes de unión
|
EP2168599B1
(en)
|
2007-06-27 |
2016-08-10 |
Osaka University |
Cancer remedy containing antibody against peptide encoded by exon-17 of periostin
|
EP2014681A1
(en)
|
2007-07-12 |
2009-01-14 |
Pierre Fabre Medicament |
Novel antibodies inhibiting c-met dimerization, and uses thereof
|
PT2175884T
(pt)
|
2007-07-12 |
2016-09-21 |
Gitr Inc |
Terapias de combinação empregando moléculas de ligação a gitr
|
WO2009029342A2
(en)
|
2007-07-13 |
2009-03-05 |
The Johns Hopkins University |
B7-dc variants
|
AU2008299784B9
(en)
|
2007-08-02 |
2015-06-18 |
Gilead Biologics, Inc. |
LOX and LOXL2 inhibitors and uses thereof
|
MY150621A
(en)
|
2007-08-30 |
2014-02-14 |
Daiichi Sankyo Co Ltd |
Anti-epha2 antibody
|
JPWO2009031230A1
(ja)
*
|
2007-09-06 |
2010-12-09 |
国立大学法人大阪大学 |
抗cd20モノクローナル抗体
|
EP2197893B1
(en)
|
2007-09-07 |
2013-07-24 |
Dyadic International, Inc. |
Novel fungal enzymes
|
EP2185592B1
(en)
|
2007-09-13 |
2013-01-23 |
University Of Zurich Prorektorat Forschung |
Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
|
US20100226925A1
(en)
|
2007-09-14 |
2010-09-09 |
Amgen Inc. |
Homogeneous Antibody Populations
|
RS53174B
(en)
|
2007-10-05 |
2014-06-30 |
Genentech Inc. |
USE OF ANTIAMYLOID BETA ANTIBODY IN THE EVENT OF ANY DISEASE
|
CN108130327A
(zh)
|
2007-10-11 |
2018-06-08 |
第三共株式会社 |
靶向破骨细胞相关蛋白Siglec-15的抗体
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
AU2008312802A1
(en)
|
2007-10-19 |
2009-04-23 |
Immunas Pharma, Inc. |
Antibody capable of specifically binding to abeta oligomer, and use thereof
|
CA2704447A1
(en)
|
2007-11-01 |
2009-05-07 |
University Of Iowa Research Foundation |
Predicting amd with snps within or near c2, factor b, plekha1, htra1, prelp, or loc387715
|
JP5698534B2
(ja)
|
2007-11-02 |
2015-04-08 |
ノバルティス アーゲー |
改良されたnogo−a結合分子およびその医薬的使用
|
JP2011514881A
(ja)
|
2007-11-09 |
2011-05-12 |
ザ ソルク インスティテュート フォー バイオロジカル スタディーズ |
免疫増強剤としてのtam受容体阻害剤の使用および免疫抑制剤としてのtam活性化剤の使用
|
NZ585465A
(en)
|
2007-11-12 |
2012-12-21 |
|
Monoclonal antibodies which bind to the extracellular domain of the axl receptor tyrosine kinase
|
MX2010005860A
(es)
|
2007-11-28 |
2010-06-22 |
Univ Pennsylvania |
Adenovirus simianos de la subfamilia c sadv-40, sadv-31 y sadv-34 y usos de los mismos.
|
PL2220241T3
(pl)
|
2007-11-28 |
2017-06-30 |
The Trustees Of The University Of Pennsylvania |
Adenowirus zawierający kapsydowe białko heksonu SAdV-39 małpiego adenowirusa E oraz jego zastosowanie
|
US8815237B2
(en)
|
2007-12-05 |
2014-08-26 |
Massachusetts Institute Of Technology |
Aglycosylated immunoglobulin mutants
|
EP2231181B1
(en)
|
2007-12-17 |
2016-02-17 |
Marfl AB |
New vaccine for the treatment of mycobacterium related disorders
|
US20100291070A1
(en)
|
2007-12-25 |
2010-11-18 |
Meiji Seika Kaisha, Ltd. |
Type iii secretion system component protein pa1698 of pseudomonas aeruginosa
|
BRPI0821949B1
(pt)
|
2007-12-28 |
2022-12-06 |
University Of Tennessee Research Foundation |
Anticorpos ou fragmentos de ligação ao antígeno destes, seus usos, seu método de preparação, suas composições farmacêuticas, e hibridomas
|
BRPI0905656B8
(pt)
|
2008-01-11 |
2021-05-25 |
Astellas Pharma Inc |
anticorpo humanizado a9-integrina anti-humana, fármaco terapêutico para artrite rematóide e uso do anticorpo humanizado a9-integrina anti-humana.
|
HUE031207T2
(hu)
|
2008-01-11 |
2017-07-28 |
Adheron Therapeutics Inc |
Cadherin-11 EC1 domén elleni antitestek gyulladásos ízületi rendellenességek kezeléséhez
|
EP2245156A4
(en)
*
|
2008-01-11 |
2011-02-02 |
Gene Techno Science Co Ltd |
HUMANIZED ANTI-9 INTEGRIN ANTIBODIES AND USES THEREOF
|
ES2617604T3
(es)
|
2008-02-08 |
2017-06-19 |
Immunas Pharma, Inc. |
Anticuerpos capaces de unirse específicamente a oligómeros de beta amiloides, y su utilización
|
WO2009136977A2
(en)
|
2008-03-04 |
2009-11-12 |
The Trustees Of The University Of Pennsylvania |
Simian adenoviruses sadv-36,-42.1, -42.2, and -44 and uses thereof
|
BRPI0909048A2
(pt)
|
2008-03-13 |
2015-11-24 |
Biotest Ag |
composição farmacêutica, e, método de tratamento de uma doença autoimune
|
JP5795167B2
(ja)
|
2008-03-13 |
2015-10-14 |
バイオテスト・アクチエンゲゼルシヤフト |
疾患治療剤
|
JP5604311B2
(ja)
|
2008-03-13 |
2014-10-08 |
バイオテスト・アクチエンゲゼルシヤフト |
疾患治療剤
|
WO2009116670A1
(ja)
|
2008-03-17 |
2009-09-24 |
株式会社リブテック |
in vivoで抗腫瘍活性を有する抗ヒトDlk-1抗体
|
WO2009115531A2
(en)
|
2008-03-17 |
2009-09-24 |
Universitätsklinikum Münster |
Yopm as delivery vehicle for cargo molecules and as biological therapeutic for immunomodulation of inflammatory reactions
|
US8241643B2
(en)
|
2008-03-17 |
2012-08-14 |
Intercell Ag |
Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto
|
US20110028697A1
(en)
|
2008-03-27 |
2011-02-03 |
Takara Bio Inc. |
Prophylactic/therapeutic agent for infectious disease
|
CA2720699C
(en)
|
2008-04-11 |
2018-01-02 |
Seattle Genetics, Inc. |
Detection and treatment of pancreatic, ovarian and other cancers using antibodies that specifically bind to denatured cd70
|
EP2113255A1
(en)
|
2008-05-02 |
2009-11-04 |
f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. |
Cytotoxic immunoglobulin
|
EP2282773B1
(en)
|
2008-05-02 |
2014-01-15 |
Seattle Genetics, Inc. |
Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
|
CA3138282A1
(en)
|
2008-06-02 |
2009-12-10 |
Dana-Farber Cancer Institute, Inc. |
Xbp1, cd138, and cs1 peptides
|
EP2319869B1
(en)
|
2008-06-20 |
2016-08-17 |
National University Corporation Okayama University |
ANTIBODY AGAINST OXIDIZED LDL/ß²GPI COMPLEX AND USE OF THE SAME
|
CN102076716A
(zh)
|
2008-06-25 |
2011-05-25 |
艾斯巴技术,爱尔康生物医药研究装置有限责任公司 |
抑制TNFα的稳定和可溶的抗体
|
ES2677003T3
(es)
|
2008-06-25 |
2018-07-27 |
Esbatech, An Alcon Biomedical Research Unit Llc |
Humanización de anticuerpos de conejo utilizando un marco universal de anticuerpos
|
SI3628686T1
(sl)
|
2008-06-25 |
2022-01-31 |
Novartis Ag |
Humaniziranje zajčjih protiteles z uporabo univerzalnega ogrodja protitelesa
|
NZ590268A
(en)
|
2008-07-08 |
2012-11-30 |
Incyte Corp |
1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
|
EP2322610B1
(en)
|
2008-07-16 |
2016-12-14 |
Medical and Biological Laboratories Co., Ltd. |
Anti-human clcp1 antibody and use thereof
|
RU2492871C2
(ru)
|
2008-08-01 |
2013-09-20 |
АКСИС, Инс. |
Терапевтическое или профилактическое средство для лечения остеоартрита
|
US8795981B2
(en)
|
2008-08-08 |
2014-08-05 |
Molecular Devices, Llc |
Cell detection
|
US8417011B2
(en)
|
2008-09-18 |
2013-04-09 |
Molecular Devices (New Milton) Ltd. |
Colony detection
|
EP2172485A1
(en)
|
2008-10-01 |
2010-04-07 |
Pierre Fabre Medicament |
Novel anti CXCR4 antibodies and their use for the treatment of cancer
|
US8715654B2
(en)
|
2008-10-02 |
2014-05-06 |
Celtaxsys, Inc. |
Methods of modulating the negative chemotaxis of immune cells
|
KR20160017117A
(ko)
|
2008-10-09 |
2016-02-15 |
미네르바 바이오테크놀로지 코포레이션 |
세포내에서 다능성을 유도하기 위한 방법
|
DK3199553T3
(da)
|
2008-10-29 |
2019-07-22 |
Circular Commitment Company |
Fremgangsmåder og midler til diagnosticering og behandling af hepatocellulært carcinom
|
US9067981B1
(en)
|
2008-10-30 |
2015-06-30 |
Janssen Sciences Ireland Uc |
Hybrid amyloid-beta antibodies
|
JP5809978B2
(ja)
|
2008-10-31 |
2015-11-11 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
サルアデノウイルスSAdV−43、−45、−46、−47、−48、−49および−50ならびにそれらの用途
|
AR074439A1
(es)
|
2008-12-02 |
2011-01-19 |
Pf Medicament |
Anticuerpo anti-cmet (receptor c-met)
|
US8545839B2
(en)
|
2008-12-02 |
2013-10-01 |
Pierre Fabre Medicament |
Anti-c-Met antibody
|
US9469691B2
(en)
|
2008-12-02 |
2016-10-18 |
Pierre Fabre Medicament |
Anti-cMET antibody
|
DK2949666T3
(en)
|
2008-12-19 |
2019-03-25 |
Biogen Int Neuroscience Gmbh |
HUMAN ANTI-ALPHA SYNUCLEIN ANTIBODIES
|
US8313915B2
(en)
|
2009-01-21 |
2012-11-20 |
Gundersen Lutheran Medical Foundation, Inc. |
Early detection of canine lyme disease by specific peptides and antibodies
|
US20100260752A1
(en)
|
2009-01-23 |
2010-10-14 |
Biosynexus Incorporated |
Opsonic and protective antibodies specific for lipoteichoic acid of gram positive bacteria
|
EP2424882A2
(en)
|
2009-02-05 |
2012-03-07 |
Intercell AG |
Peptides protective against e. faecalis, methods and uses relating thereto
|
EP2405938A2
(en)
|
2009-02-13 |
2012-01-18 |
Intercell AG |
Nontypable haemophilus influenzae antigens
|
WO2010096658A1
(en)
|
2009-02-19 |
2010-08-26 |
The Cleveland Clinic Foundation |
Corin as a marker for heart failure
|
JP5883653B2
(ja)
|
2009-03-10 |
2016-03-15 |
ベイラー リサーチ インスティテュートBaylor Research Institute |
抗原提示細胞ターゲティング抗ウイルスワクチン
|
PT2406286T
(pt)
|
2009-03-10 |
2016-08-19 |
Baylor Res Inst |
Anticorpos anti-cd40 e seus usos
|
CN108373509A
(zh)
|
2009-03-10 |
2018-08-07 |
贝勒研究院 |
靶向抗原呈递细胞的抗病毒疫苗
|
WO2010109924A1
(ja)
|
2009-03-25 |
2010-09-30 |
国立大学法人東北大学 |
Lh型二重特異性抗体
|
KR101690340B1
(ko)
|
2009-04-09 |
2016-12-27 |
다이이찌 산쿄 가부시키가이샤 |
항 Siglec-15 항체
|
US20120121706A1
(en)
|
2009-04-10 |
2012-05-17 |
Tufts Medical Center, Inc. |
PAR-1 Activation by Metalloproteinase-1 (MMP-1)
|
CN102459335B
(zh)
|
2009-04-17 |
2015-11-25 |
伊缪纳斯制药株式会社 |
特异性结合Aβ寡聚体的抗体及其用途
|
BRPI1012162A2
(pt)
|
2009-04-29 |
2016-01-12 |
Abbott Biotech Ltd |
dispositivo de injeção automática
|
EP2246364A1
(en)
|
2009-04-29 |
2010-11-03 |
Pierre Fabre Médicament |
Anti CXCR4 antibodies for the treatment of HIV
|
EP2270053A1
(en)
|
2009-05-11 |
2011-01-05 |
U3 Pharma GmbH |
Humanized AXL antibodies
|
EP2435559A1
(en)
|
2009-05-29 |
2012-04-04 |
The Trustees Of The University Of Pennsylvania |
Simian adenovirus 41 and uses thereof
|
EP2260864A1
(en)
|
2009-06-10 |
2010-12-15 |
University of Melbourne |
Therapeutic applications
|
TWI513465B
(zh)
|
2009-06-25 |
2015-12-21 |
Regeneron Pharma |
以dll4拮抗劑與化學治療劑治療癌症之方法
|
CA2767409C
(en)
|
2009-07-24 |
2018-10-30 |
The Regents Of The University Of California |
Methods and compositions for treating and preventing disease associated with .alpha.v.beta.5 integrin
|
CA2768330A1
(en)
|
2009-07-28 |
2011-02-03 |
F. Hoffmann-La Roche Ag |
Non-invasive in vivo optical imaging method
|
AU2010280981B2
(en)
|
2009-08-05 |
2016-01-28 |
Nexigen Gmbh |
Human HCV-interacting proteins and methods of use
|
WO2011024114A1
(en)
|
2009-08-25 |
2011-03-03 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Targeting extracellular matrix molecules for the treatment of cancer
|
TWI412375B
(zh)
|
2009-08-28 |
2013-10-21 |
Roche Glycart Ag |
人類化抗cdcp1抗體
|
WO2011026122A2
(en)
|
2009-08-31 |
2011-03-03 |
Amplimmune, Inc. |
B7-h4 fusion proteins and methods of use thereof
|
EP2477647B1
(en)
|
2009-09-14 |
2016-01-13 |
The Regents of the University of Colorado |
Modulation of yeast-based immunotherapy products and responses
|
EP2305285A1
(en)
|
2009-09-29 |
2011-04-06 |
Julius-Maximilians-Universität Würzburg |
Means and methods for treating ischemic conditions
|
US8568726B2
(en)
|
2009-10-06 |
2013-10-29 |
Medimmune Limited |
RSV specific binding molecule
|
EP2308897A1
(en)
|
2009-10-09 |
2011-04-13 |
Pierre Fabre Medicament |
Chimeric antibodies specific for CD151 and use thereof in the treatment of cancer
|
AU2010303156B2
(en)
|
2009-10-11 |
2016-02-04 |
Biogen Ma Inc. |
Anti-VLA-4 related assays
|
WO2011062112A1
(ja)
|
2009-11-18 |
2011-05-26 |
国立大学法人東北大学 |
ヒト型化抗egfr抗体可変領域の高機能性変異体
|
EP2332929A1
(en)
|
2009-11-25 |
2011-06-15 |
ArisGen SA |
Orthoester derivatives of crown ethers as carriers for pharmaceutical and diagnostic compositions
|
GB0920944D0
(en)
|
2009-11-30 |
2010-01-13 |
Biotest Ag |
Agents for treating disease
|
WO2011068870A2
(en)
|
2009-12-01 |
2011-06-09 |
President And Fellows Of Harvard College |
Modulation of nk cell antigen specific effector activity by modulation of cxcr6 (cd186)
|
JP2013514388A
(ja)
|
2009-12-16 |
2013-04-25 |
フィリップ ボッシュ, |
間質性膀胱炎の処置の方法
|
US9221759B2
(en)
|
2010-01-13 |
2015-12-29 |
Rutgers, The State University Of New Jersey |
Fluorophore chelated lanthanide luminescent probes with improved quantum efficiency
|
CA2787755A1
(en)
|
2010-01-20 |
2011-07-28 |
Tolerx, Inc. |
Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments
|
EP2525813B1
(en)
|
2010-01-20 |
2017-01-04 |
Merck Sharp & Dohme Corp. |
Anti-ilt5 antibodies and ilt5-binding antibody fragments
|
JP2012246222A
(ja)
|
2010-01-29 |
2012-12-13 |
Axis Inc |
変形性関節症治療剤または予防剤を製造するための使用
|
KR101684246B1
(ko)
|
2010-01-29 |
2016-12-08 |
가부시키가이샤 아크시스 |
변형성 관절증 치료제를 포함하는 주사제
|
US20130011407A1
(en)
|
2010-01-29 |
2013-01-10 |
Axis Inc. |
Pharmaceutical composition for treatment or prevention of osteoarthritis, and method of production therefor
|
EP2531613A2
(en)
|
2010-02-02 |
2012-12-12 |
Abbott Biotechnology Ltd. |
Methods and compositions for predicting responsiveness to treatment with tnf-alpha inhibitor
|
ES2668645T3
(es)
|
2010-02-08 |
2018-05-21 |
Agensys, Inc. |
Conjugados de fármaco y anticuerpo (ADC) que se unen a proteínas 161P2F10B
|
JP2013520173A
(ja)
|
2010-02-18 |
2013-06-06 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
インテグリンαvβ8中和抗体
|
WO2011109398A2
(en)
|
2010-03-02 |
2011-09-09 |
President And Fellows Of Harvard College |
Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
|
WO2011106885A1
(en)
|
2010-03-03 |
2011-09-09 |
The University Of British Columbia |
Oligomer-specific amyloid beta epitope and antibodies
|
CA2794551A1
(en)
|
2010-03-26 |
2011-09-29 |
Westfaelische Wilhelms-Universitaet Muenster |
Substitute therapy for glucocorticoids
|
EP2371863A1
(en)
|
2010-03-30 |
2011-10-05 |
Pierre Fabre Médicament |
Humanized anti CXCR4 antibodies for the treatment of cancer
|
US8420785B2
(en)
|
2010-04-09 |
2013-04-16 |
Critical Care Diagnostics, Inc. |
Soluble human ST-2 antibodies and assays
|
LT3202789T
(lt)
|
2010-04-16 |
2020-06-10 |
Biogen Ma Inc. |
Antikūnai prieš vla-4
|
KR102071212B1
(ko)
|
2010-04-21 |
2020-01-30 |
애브비 바이오테크놀로지 리미티드 |
치료제의 제어된 전달을 위한 착용형 자동 주사 디바이스
|
WO2011138462A1
(en)
|
2010-05-07 |
2011-11-10 |
F. Hoffmann-La Roche Ag |
Diagnostic method for the detection of cells ex vivo
|
ES2664809T3
(es)
|
2010-05-17 |
2018-04-23 |
Chiome Bioscience Inc. |
Anticuerpo anti-TROP-2 humano que tiene actividad antitumoral in vivo
|
US20110287018A1
(en)
|
2010-05-19 |
2011-11-24 |
Philip Bosch |
Methods of Treating Interstitial Cystitis
|
WO2012005076A1
(ja)
|
2010-07-08 |
2012-01-12 |
本田技研工業株式会社 |
高周波加熱用コイル
|
MX338640B
(es)
|
2010-07-14 |
2016-04-25 |
Merck Sharp & Dohme |
Anticuerpo monoclonal anti-ligando difundible derivado de amiloide beta y usos de los mismos.
|
EP2593128B1
(en)
|
2010-07-15 |
2018-01-10 |
Adheron Therapeutics, Inc. |
Humanized antibodies targeting the ec1 domain of cadherin-11 and related compositions and methods
|
SI2598526T1
(sl)
|
2010-07-29 |
2018-10-30 |
Eleven Biotherapeutics,Inc |
Agonisti in antagonisti himernih receptorjev IL-1 tipa 1
|
WO2012016173A2
(en)
|
2010-07-30 |
2012-02-02 |
Ac Immune S.A. |
Safe and functional humanized antibodies
|
JP2012034668A
(ja)
|
2010-08-12 |
2012-02-23 |
Tohoku Univ |
ヒト型化抗egfr抗体リジン置換可変領域断片及びその利用
|
WO2012027494A1
(en)
|
2010-08-24 |
2012-03-01 |
Regents Of The University Of Minnesota |
Bispecific targeting reagents
|
US9034333B2
(en)
|
2010-08-27 |
2015-05-19 |
University Of Zurich |
Method for target and drug validation in inflammatory and/or cardiovascular diseases
|
CA2807244A1
(en)
|
2010-08-27 |
2012-03-01 |
University Of Zurich |
A novel diagnostic and therapeutic target in inflammatory and/or cardiovascular diseases
|
WO2012028697A1
(en)
|
2010-09-01 |
2012-03-08 |
Eth Zürich, Institute Of Molecular Biology And Biophysics |
Affinity purification system based on donor strand complementation
|
US20120244141A1
(en)
|
2010-09-28 |
2012-09-27 |
Boehringer Ingelheim International Gmbh |
Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
|
US8497138B2
(en)
|
2010-09-30 |
2013-07-30 |
Genetix Limited |
Method for cell selection
|
US9675693B2
(en)
|
2010-09-30 |
2017-06-13 |
Riken |
Methods and drugs targeting Eva1 or Ceacam1 gene expression for treatment and diagnosing of glioma
|
NZ609984A
(en)
|
2010-10-11 |
2015-05-29 |
Biogen Idec Internat Neuroscience Gmbh |
Human anti-tau antibodies
|
MX354095B
(es)
|
2010-10-13 |
2018-02-12 |
Janssen Biotech Inc |
Anticuerpos de oncostatina m humana y metodos de uso.
|
EP2630160B1
(en)
|
2010-10-18 |
2016-11-09 |
MediaPharma S.r.l. |
Erbb3 binding antibody
|
UY33679A
(es)
|
2010-10-22 |
2012-03-30 |
Esbatech |
Anticuerpos estables y solubles
|
CN106563128B
(zh)
|
2010-10-22 |
2020-05-22 |
西雅图遗传学公司 |
以奥里斯他汀为主的抗体药物结合物和结合mTOR的抑制剂在制备治疗癌症药物中的用途
|
PL3326645T3
(pl)
|
2010-10-25 |
2020-09-21 |
Biogen Ma Inc. |
Sposoby określania różnic w aktywności integryn alfa-4 przez korelowanie różnic w poziomach sVCAM i/lub sMAdCAM
|
JP2014504147A
(ja)
|
2010-10-27 |
2014-02-20 |
ピエール、ファーブル、メディカマン |
Hivの治療用抗体
|
ES2675847T3
(es)
|
2010-10-29 |
2018-07-13 |
Daiichi Sankyo Company, Limited |
Nuevo anticuerpo anti-DR5
|
EP2640425A2
(en)
|
2010-11-18 |
2013-09-25 |
Beth Israel Deaconess Medical Center, Inc. |
Methods of treating obesity by inhibiting nicotinamide n-methyl transferase (nnmt)
|
SG191716A1
(en)
|
2010-11-19 |
2013-08-30 |
Toshio Imai |
Neutralizing anti-ccl20 antibodies
|
WO2012071318A2
(en)
|
2010-11-23 |
2012-05-31 |
The Trustees Of The University Of Pennsylvania |
Subfamily e simian adenoviruses a1321, a1325, a1295, a1309, a1316 and a1322 and uses thereof
|
CN103380145B
(zh)
|
2010-12-17 |
2016-10-12 |
生物控股有限公司 |
人类抗-sod1抗体
|
WO2012090939A1
(ja)
|
2010-12-27 |
2012-07-05 |
国立大学法人名古屋大学 |
受容体型チロシンキナーゼが仲介する癌細胞の生存促進性シグナルを抑制する方法
|
EP2663580B1
(en)
|
2011-01-10 |
2016-12-07 |
CT Atlantic Ltd. |
Combination therapy including tumor associated antigen binding antibodies
|
ES2634098T3
(es)
|
2011-01-14 |
2017-09-26 |
The Regents Of The University Of California |
Anticuerpos terapéuticos contra la proteína ROR-1 y procedimientos para el uso de los mismos.
|
SG192119A1
(en)
|
2011-01-24 |
2013-08-30 |
Abbvie Biotechnology Ltd |
Automatic injection devices having overmolded gripping surfaces
|
WO2012104824A1
(en)
|
2011-02-04 |
2012-08-09 |
Ecole polytechnique fédérale de Lausanne (EPFL) |
Therapeutic antibodies targeting app-c99
|
WO2012107589A1
(en)
|
2011-02-11 |
2012-08-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
|
WO2012110843A1
(en)
|
2011-02-18 |
2012-08-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for promoting fibrinolysis and thrombolysis
|
EP2678026B1
(en)
|
2011-02-21 |
2016-05-18 |
The University of Zurich |
Ankyrin g for use in the treatment of neurodegenerative disorders
|
EP2683413A1
(en)
|
2011-03-07 |
2014-01-15 |
F.Hoffmann-La Roche Ag |
In vivo selection of therapeutically active antibodies
|
WO2012119999A1
(en)
|
2011-03-07 |
2012-09-13 |
F. Hoffmann-La Roche Ag |
Means and methods for in vivo testing of therapeutic antibodies
|
US10139420B2
(en)
|
2011-03-09 |
2018-11-27 |
ISNERM (Institut National de la Sante et de la Recherche Medicale) |
Methods for treating vaso-occlusive crisis using non-modified annexin V
|
WO2012125680A1
(en)
|
2011-03-16 |
2012-09-20 |
Novartis Ag |
Methods of treating vasculitis using an il-17 binding molecule
|
WO2012123590A1
(de)
|
2011-03-17 |
2012-09-20 |
Miltenyi Biotec Gmbh |
Tcralpha/beta-depletierte zellpräparationen
|
US20120301465A1
(en)
|
2011-03-25 |
2012-11-29 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Compositions and methods to immunize against hepatitis c virus
|
TW201249867A
(en)
|
2011-04-01 |
2012-12-16 |
Astellas Pharma Inc |
Novel anti-human il-23 receptor antibody
|
JP6066995B2
(ja)
|
2011-04-21 |
2017-01-25 |
アッヴィ・インコーポレイテッド |
装着型自動注射装置
|
US9371395B2
(en)
|
2011-04-25 |
2016-06-21 |
Daiichi Sankyo Company, Limited |
Anti B7-H3 antibody
|
CN108969761A
(zh)
|
2011-05-02 |
2018-12-11 |
米伦纽姆医药公司 |
抗α4β7抗体的制剂
|
UA116189C2
(uk)
|
2011-05-02 |
2018-02-26 |
Мілленніум Фармасьютікалз, Інк. |
КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
|
UA117218C2
(uk)
|
2011-05-05 |
2018-07-10 |
Мерк Патент Гмбх |
Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
|
WO2012154889A1
(en)
|
2011-05-09 |
2012-11-15 |
The Cleveland Clinic Foundation |
Serum s100b and uses thereof
|
WO2012163848A1
(en)
|
2011-05-27 |
2012-12-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of crohn's disease
|
EP2530088A1
(en)
|
2011-05-30 |
2012-12-05 |
Klinikum rechts der Isar der Technischen Universität München |
Means and methods for diagnosing and treating multiple sclerosis
|
EP2714742A1
(en)
|
2011-06-03 |
2014-04-09 |
CT Atlantic Ltd. |
Magea3 binding antibodies
|
JP2014524891A
(ja)
|
2011-06-03 |
2014-09-25 |
シーティー アトランティック リミテッド |
Magea3結合抗体
|
JP6305919B2
(ja)
|
2011-06-06 |
2018-04-04 |
プロセナ バイオサイエンシーズ リミテッド |
Mcamアンタゴニスト及び治療の方法
|
WO2012172449A1
(en)
|
2011-06-13 |
2012-12-20 |
Pfizer Inc. |
Lactams as beta secretase inhibitors
|
US20140120555A1
(en)
|
2011-06-20 |
2014-05-01 |
Pierre Fabre Medicament |
Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
|
DK2723379T3
(en)
|
2011-06-23 |
2018-10-15 |
Biogen Int Neuroscience Gmbh |
ANTI-ALPHA SYNUCLEIN BINDING MOLECULES
|
DE202011103324U1
(de)
|
2011-07-12 |
2012-01-02 |
Nekonal S.A.R.L. |
Therapeutische anti-TIRC7 Antikörper für die Verwendung in Immun und anderen Krankheiten
|
GB201112056D0
(en)
|
2011-07-14 |
2011-08-31 |
Univ Leuven Kath |
Antibodies
|
US20140308275A1
(en)
|
2011-07-27 |
2014-10-16 |
Inserm (Institut National De La Sante Et De La Recherche Medicale |
Methods for diagnosing and treating myhre syndrome
|
DK2743348T3
(en)
|
2011-08-11 |
2018-02-26 |
Astellas Pharma Inc |
Hitherto UNKNOWN ANTI-HUMAN NGF ANTIBODY
|
EP2741777B1
(en)
|
2011-08-12 |
2017-01-18 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical compositions for treatment of pulmonary hypertension
|
EP2743699A4
(en)
|
2011-08-12 |
2015-04-08 |
Nat Inst Infectious Diseases |
METHOD FOR THE TEST, PREVENTION AND TREATMENT OF ASPERGILLUS FUMIGATUS INFECTIOUS DISEASE, AND COMPOSITION
|
GB201116092D0
(en)
|
2011-09-16 |
2011-11-02 |
Bioceros B V |
Antibodies and uses thereof
|
MY183989A
(en)
|
2011-09-19 |
2021-03-17 |
Axon Neuroscience Se |
Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
|
GB2495115A
(en)
*
|
2011-09-29 |
2013-04-03 |
Oxford Plastic Sys Ltd |
Base for supporting temporary fence panels or posts.
|
TW201329105A
(zh)
|
2011-10-04 |
2013-07-16 |
Thr Trustees Of Columbia University In The City Of New York |
人類notch1引誘物
|
WO2013050540A1
(en)
|
2011-10-05 |
2013-04-11 |
University Of Bremen |
Wnt4 and med12 for use in the diagnosis and treatment of tumor diseases
|
WO2013050441A1
(en)
|
2011-10-05 |
2013-04-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for inhibiting or preventing platelet aggregation
|
WO2013054320A1
(en)
|
2011-10-11 |
2013-04-18 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
|
US10378060B2
(en)
|
2011-10-14 |
2019-08-13 |
Dana-Farber Cancer Institute, Inc. |
ZNF365/ZFP365 biomarker predictive of anti-cancer response
|
CA2852244C
(en)
|
2011-10-17 |
2023-10-17 |
Minerva Biotechnologies Corporation |
Media for stem cell proliferation and induction
|
US20140248284A1
(en)
|
2011-10-20 |
2014-09-04 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods for the detection and the treatment of cardiac remodeling
|
EP2589609A1
(en)
|
2011-11-03 |
2013-05-08 |
Pierre Fabre Medicament |
Antigen binding protein and its use as addressing product for the treatment of cancer
|
US9427464B2
(en)
|
2011-11-22 |
2016-08-30 |
Chiome Bioscience Inc. |
Anti-human TROP-2 antibody having an antitumor activity in vivo
|
WO2013076194A1
(en)
|
2011-11-22 |
2013-05-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for reducing airway hyperresponse
|
JP6082402B2
(ja)
|
2011-11-28 |
2017-02-15 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
加齢に伴う機能障害の処置に使用するための薬学的組成物
|
EP2602621A1
(en)
|
2011-12-08 |
2013-06-12 |
Julius-Maximilians-Universität Würzburg |
LASP-1, a novel urinary marker for transitional cell carcinoma detection
|
EP3272364B1
(en)
*
|
2011-12-13 |
2020-07-29 |
Nordic Nanovector ASA |
Chimeric therapeutic anti-cd37 antibodie hh1
|
FR2984750B1
(fr)
|
2011-12-23 |
2014-01-10 |
Lfb Biotechnologies |
Nouvelles compositions pharmaceutiques comprenant un anticorps liant le recepteur humain de l'hormone anti-mullerienne de type ii
|
EP2794660A2
(en)
|
2011-12-23 |
2014-10-29 |
Phenoquest AG |
Antibodies for the treatment and diagnosis of affective and anxiety disorders
|
ES2964168T3
(es)
|
2011-12-28 |
2024-04-04 |
Immunoqure Ag |
Anticuerpo anti-interleucina 22 (IL-22) y usos del mismo
|
SG11201403756PA
(en)
|
2012-01-01 |
2014-11-27 |
Qbi Entpr Ltd |
Endo180-targeted particles for selective delivery of therapeutic and diagnostic agents
|
CA2864092C
(en)
|
2012-02-10 |
2021-06-29 |
Seattle Genetics, Inc. |
Detection and treatment of cd30+ cancers
|
WO2013123114A2
(en)
|
2012-02-16 |
2013-08-22 |
Santarus, Inc. |
Antibody formulations
|
CN104136464A
(zh)
|
2012-02-23 |
2014-11-05 |
U3制药有限公司 |
用于调节放射敏感性的her3抑制剂
|
EP2821416B1
(en)
|
2012-02-28 |
2018-10-03 |
Astellas Pharma Inc. |
Novel anti-human il-23 receptor antibody
|
NZ629697A
(en)
|
2012-03-15 |
2017-01-27 |
Janssen Biotech Inc |
Human anti-cd27 antibodies, methods and uses
|
US9567392B2
(en)
|
2012-03-20 |
2017-02-14 |
Biogen Ma Inc. |
JCV neutralizing antibodies
|
TW201345925A
(zh)
|
2012-03-30 |
2013-11-16 |
Daiichi Sankyo Co Ltd |
新穎抗siglec-15抗體
|
ES2660472T3
(es)
|
2012-03-30 |
2018-03-22 |
Daiichi Sankyo Company, Limited |
Anticuerpo anti-Siglec-15 modificado con CDR
|
EP2833900B1
(en)
|
2012-04-01 |
2018-09-19 |
Technion Research & Development Foundation Limited |
Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies
|
CN103382223B
(zh)
|
2012-04-01 |
2015-06-10 |
上海益杰生物技术有限公司 |
针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽
|
CA2869394A1
(en)
|
2012-04-02 |
2013-10-10 |
Gundersen Lutheran Health System, Inc. |
Reagents, methods, and kits for the classification of cancer
|
TWI669313B
(zh)
|
2012-04-09 |
2019-08-21 |
第一三共股份有限公司 |
抗FGFR2抗體及其製造方法、及檢測或測定人類FGFR2IIIb之方法
|
MX356749B
(es)
|
2012-04-27 |
2018-06-12 |
Daiichi Sankyo Co Ltd |
Anticuerpo anti-homologo 4 de roundabout (robo4).
|
US9062120B2
(en)
|
2012-05-02 |
2015-06-23 |
Janssen Biotech, Inc. |
Binding proteins having tethered light chains
|
EP2848633B1
(en)
|
2012-05-11 |
2019-02-06 |
Microbial Chemistry Research Foundation |
Anti-cxadr antibody
|
JP6122948B2
(ja)
|
2012-05-15 |
2017-04-26 |
モルフォテック, インコーポレイテッド |
胃癌の治療のための方法
|
MX358019B
(es)
|
2012-05-18 |
2018-08-02 |
Univ Pennsylvania |
Adenovirus de simio de la subfamilia e a1302, a1320, a1331 y a1337 y sus usos.
|
EP2852679A1
(en)
|
2012-05-22 |
2015-04-01 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods for diagnosing and treating focal segmental glomerulosclerosis
|
MX369626B
(es)
|
2012-05-24 |
2019-11-13 |
Mountgate Group Ltd |
Composiciones y metodos relacionados con la prevencion y el tratamiento de infecciones por rabia.
|
PL2872171T3
(pl)
|
2012-07-13 |
2021-07-12 |
The Trustees Of The University Of Pennsylvania |
Kontrola toksyczności wobec aktywności przeciwnowotworowej CAR
|
EP2875049B1
(en)
|
2012-07-18 |
2018-12-26 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Methods for preventing and treating chronic kidney disease (ckd)
|
KR102165464B1
(ko)
|
2012-07-19 |
2020-10-14 |
레드우드 바이오사이언스 인코포레이티드 |
Cd22에 대해 특이적인 항체 및 이들의 사용 방법
|
AU2013297478B2
(en)
|
2012-07-30 |
2018-12-20 |
Medical & Biological Laboratories Co., Ltd. |
Monoclonal antibody against human midkine
|
MY181648A
(en)
|
2012-08-24 |
2020-12-30 |
Univ California |
Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
|
TW201922795A
(zh)
|
2012-09-10 |
2019-06-16 |
愛爾蘭商尼歐托普生物科學公司 |
抗mcam抗體及相關使用方法
|
SG11201501924UA
(en)
|
2012-09-13 |
2015-05-28 |
Chugai Pharmaceutical Co Ltd |
Gene knock-in non-human animal
|
EP2711016A1
(en)
|
2012-09-21 |
2014-03-26 |
Covagen AG |
Novel IL-17A binding molecules and medical uses thereof
|
SI2905335T1
(en)
|
2012-10-03 |
2018-04-30 |
Chiome Bioscience Inc. |
PROTITEL AGAINST HUMANEMU DLK-1 WITH PROTITUM ACTIVITY AND VIVO
|
EP3677310A1
(en)
|
2012-10-08 |
2020-07-08 |
St. Jude Children's Research Hospital |
Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis
|
PT2907824T
(pt)
|
2012-10-11 |
2018-06-07 |
Daiichi Sankyo Co Ltd |
Conjugado de anticorpo-fármaco
|
DE102012020496A1
(de)
|
2012-10-18 |
2014-04-24 |
Charité - Universitätsmedizin Berlin |
Biomarker zur Diagnostik und Behandlung von Neurofibromatose Typ 1
|
WO2014061277A1
(ja)
|
2012-10-19 |
2014-04-24 |
第一三共株式会社 |
親水性構造を含むリンカーで結合させた抗体-薬物コンジュゲート
|
WO2014064203A1
(en)
|
2012-10-26 |
2014-05-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Lyve-1 antagonists for preventing or treating a pathological condition associated with lymphangiogenesis
|
EP3508503B1
(en)
|
2012-11-01 |
2022-11-02 |
Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft |
Antibody against cd269 (bcma)
|
PL2914630T3
(pl)
|
2012-11-05 |
2021-09-06 |
Pierre Fabre Médicament |
Nowe białka wiążące antygen i ich zastosowanie jako produktu ukierunkowanego do leczenia raka
|
JP6445446B2
(ja)
|
2012-11-08 |
2018-12-26 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
骨転移の治療のための方法及び医薬組成物
|
TW201438736A
(zh)
|
2012-11-14 |
2014-10-16 |
Regeneron Pharma |
以dll4拮抗劑治療卵巢癌之方法
|
KR20150094658A
(ko)
|
2012-12-10 |
2015-08-19 |
바이오젠 엠에이 인코포레이티드 |
항-혈액 수지상 세포 항원 2 항체 및 이의 용도
|
WO2014096672A1
(fr)
|
2012-12-17 |
2014-06-26 |
Laboratoire Francais Du Fractionnement Et Des Biotechnologies |
Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes
|
WO2014100602A1
(en)
|
2012-12-20 |
2014-06-26 |
Hospital For Special Surgery |
Treatment of egf-receptor dependent pathologies
|
JP6284548B2
(ja)
|
2012-12-21 |
2018-02-28 |
バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. |
ヒト抗タウ抗体
|
CA2896824A1
(en)
|
2012-12-31 |
2014-07-03 |
Neurimmune Holding Ag |
Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases
|
EP2752426A1
(en)
|
2013-01-03 |
2014-07-09 |
Covagen AG |
Human serum albumin binding compounds and fusion proteins thereof
|
ES2865735T3
(es)
|
2013-01-28 |
2021-10-15 |
Evec Inc |
Anticuerpo anti-hmgb1 humanizado o fragmento de unión a antígeno del mismo
|
JP2016508606A
(ja)
|
2013-02-01 |
2016-03-22 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
トリプルネガティブ乳ガンにおける転移を予測及び予防するための方法
|
JP6357113B2
(ja)
|
2013-02-08 |
2018-07-11 |
株式会社医学生物学研究所 |
ヒトnrg1タンパク質に対する抗体
|
EP2956478A1
(en)
|
2013-02-15 |
2015-12-23 |
ESBATech - a Novartis Company LLC |
Acceptor framework for cdr grafting
|
WO2014127811A1
(en)
|
2013-02-20 |
2014-08-28 |
Esbatech - A Novartis Company Llc |
Acceptor framework for cdr grafting
|
FR3004184B1
(fr)
|
2013-02-26 |
2016-03-18 |
Agronomique Inst Nat Rech |
Anticorps anti-gluten desamide et utilisations.
|
US9429584B2
(en)
|
2013-02-28 |
2016-08-30 |
National Cancer Center |
Antibody against insoluble fibrin
|
US10227396B2
(en)
|
2013-03-08 |
2019-03-12 |
Osaka University |
Antibody against peptide encoded by Exon-21 of periostin and pharmaceutical composition for preventing or treating inflammation-associated diseases containing the same
|
US20140308239A1
(en)
|
2013-03-13 |
2014-10-16 |
Eleven Biotherapeutics, Inc. |
Chimeric cytokine formulations for ocular delivery
|
US10023608B1
(en)
|
2013-03-13 |
2018-07-17 |
Amgen Inc. |
Protein purification methods to remove impurities
|
WO2014151917A1
(en)
|
2013-03-14 |
2014-09-25 |
Ffe Therapeutics Llc |
Compositions and methods for treating angiogenesis-related disorders
|
US9302005B2
(en)
|
2013-03-14 |
2016-04-05 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
WO2014143739A2
(en)
|
2013-03-15 |
2014-09-18 |
Biogen Idec Ma Inc. |
Anti-alpha v beta 6 antibodies and uses thereof
|
EP2970475A1
(en)
|
2013-03-15 |
2016-01-20 |
Biogen MA Inc. |
Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies
|
US10035859B2
(en)
|
2013-03-15 |
2018-07-31 |
Biogen Ma Inc. |
Anti-alpha V beta 6 antibodies and uses thereof
|
MD4633B1
(ro)
|
2013-03-18 |
2019-06-30 |
Biocerox Products B.V. |
Anticorpi umanizaţi anti-CD134 (OX40) şi utilizarea acestora
|
ES2823648T3
(es)
|
2013-04-01 |
2021-05-07 |
Univ California |
Métodos y composiciones para tratar y prevenir enfermedades asociadas con la integrina AVB8
|
WO2014174596A1
(ja)
|
2013-04-23 |
2014-10-30 |
株式会社医学生物学研究所 |
ヘパリン結合上皮増殖因子様増殖因子に対する機能性モノクローナル抗体
|
US9717648B2
(en)
|
2013-04-24 |
2017-08-01 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
CN107460201A
(zh)
|
2013-05-08 |
2017-12-12 |
科济生物医药(上海)有限公司 |
编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞
|
EP3011334A1
(en)
|
2013-06-20 |
2016-04-27 |
The Trustees Of The University Of Pennsylvania |
Methods for diagnosing pancreatic cancer
|
JP6742237B2
(ja)
|
2013-07-03 |
2020-08-19 |
イムノキュア アーゲーImmunoqure Ag |
ヒト抗ifn−アルファ抗体
|
CN105517572B
(zh)
|
2013-07-05 |
2019-05-31 |
华盛顿大学商业中心 |
用于治疗癌症的中和可溶性mic的单克隆抗体
|
EP3016973A1
(en)
|
2013-07-05 |
2016-05-11 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Novel alternative splice transcripts for mhc class i related chain alpha (mica) and uses thereof
|
AR097293A1
(es)
|
2013-08-09 |
2016-03-02 |
Astellas Pharma Inc |
Anticuerpo contra el receptor de tslp humana
|
WO2015036956A1
(en)
|
2013-09-12 |
2015-03-19 |
Institut National De La Sante Et De La Recherche Medicale |
Method for in vitro quantifying allo-antibodies, auto-antibodies and/or therapeutic antibodies
|
WO2015040215A1
(en)
|
2013-09-20 |
2015-03-26 |
Westfaelische Wilhelms-Universitaet Muenster |
Cell-penetrating bacterial e3-ubiqitin-ligases for use in immunotherapy
|
JP6615100B2
(ja)
|
2013-09-24 |
2019-12-04 |
ザ ファインスタイン インスティチュート フォー メディカル リサーチ |
低温誘導性rna結合タンパク質活性を阻害するペプチド
|
WO2015048531A1
(en)
|
2013-09-26 |
2015-04-02 |
Beth Israel Deaconess Medical Center, Inc. |
Inhibition of sgk1 in the treatment of heart conditions
|
EP3061818B1
(en)
|
2013-09-30 |
2020-12-16 |
Daiichi Sankyo Company, Limited |
Anti-lps o11 antibody
|
EP3052131B1
(en)
|
2013-10-01 |
2018-12-05 |
Mayo Foundation for Medical Education and Research |
Methods for treating cancer in patients with elevated levels of bim
|
WO2015053407A1
(ja)
|
2013-10-08 |
2015-04-16 |
第一三共株式会社 |
抗fgfr2抗体と他剤の組合せ
|
WO2015069865A1
(en)
|
2013-11-06 |
2015-05-14 |
Janssen Biotech, Inc. |
Anti-ccl17 antibodies
|
JPWO2015068781A1
(ja)
|
2013-11-06 |
2017-03-09 |
国立大学法人大阪大学 |
インフルエンザウイルスa型のグループ1に対して広域な中和活性を有する抗体
|
JP2016538286A
(ja)
|
2013-11-15 |
2016-12-08 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
膵臓癌を処置するための方法及び医薬組成物
|
WO2015082446A1
(en)
|
2013-12-02 |
2015-06-11 |
F. Hoffmann-La Roche Ag |
Treatment of cancer using an anti-cdcp1 antibody and a taxane
|
US10294301B2
(en)
|
2013-12-24 |
2019-05-21 |
Astellas Pharma Inc. |
Anti-human BDCA-2 antibody
|
KR102288093B1
(ko)
|
2013-12-25 |
2021-08-09 |
다이이찌 산쿄 가부시키가이샤 |
항 trop2 항체-약물 컨쥬게이트
|
AU2015205327B2
(en)
|
2014-01-09 |
2019-02-14 |
Hadasit Medical Research Services And Development Ltd. |
Improved cell compositions and methods for cancer therapy
|
EP3094652B1
(en)
|
2014-01-13 |
2021-09-29 |
Baylor Research Institute |
Novel vaccines against hpv and hpv-related diseases
|
CN104774264B
(zh)
|
2014-01-15 |
2018-09-14 |
上海易乐生物技术有限公司 |
抗人proBDNF单克隆抗体及其在疼痛中的作用
|
KR102275925B1
(ko)
|
2014-01-31 |
2021-07-12 |
다이이찌 산쿄 가부시키가이샤 |
항-her2 항체-약물 접합체
|
WO2015124570A1
(en)
|
2014-02-18 |
2015-08-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of influenza a virus infection
|
WO2015124588A1
(en)
|
2014-02-18 |
2015-08-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of diseases mediated by the nrp-1/obr complex signaling pathway
|
EP3415160B1
(en)
|
2014-03-04 |
2021-08-18 |
Klinikum der Universität München |
Polypeptides derived from enterococcus and their use for vaccination and the generation of therapeutic antibodies
|
WO2015140351A1
(en)
|
2014-03-21 |
2015-09-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for enhancing myelination
|
WO2015145449A2
(en)
|
2014-03-27 |
2015-10-01 |
Yeda Research And Development Co. Ltd. |
T-cell receptor cdr3 peptides and antibodies
|
DK3129063T3
(da)
|
2014-04-10 |
2021-04-06 |
Daiichi Sankyo Co Ltd |
Anti-her3-antistof-lægemiddelkonjugat
|
WO2015164743A2
(en)
|
2014-04-24 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
|
MX2016013704A
(es)
|
2014-04-25 |
2017-03-31 |
Pf Medicament |
Conjugado farmaco-anticuerpo igf-1r y su uso para el tratamiento contra el cancer.
|
HUE052223T2
(hu)
|
2014-04-25 |
2021-04-28 |
Pf Medicament |
IGF-1R ellenanyag és alkalmazása rák kezelésében célzóeszközként
|
BR112016024363A2
(pt)
|
2014-04-25 |
2017-10-10 |
Pf Medicament |
conjugado de anticorpo-fármaco e seu uso para tratamento de câncer
|
US11427647B2
(en)
|
2014-04-27 |
2022-08-30 |
Famewave Ltd. |
Polynucleotides encoding humanized antibodies against CEACAM1
|
KR102452349B1
(ko)
|
2014-04-27 |
2022-10-11 |
페임웨이브 리미티드 |
Ceacam1에 대한 인간화 항체
|
WO2015179654A1
(en)
|
2014-05-22 |
2015-11-26 |
Mayo Foundation For Medical Education And Research |
Distinguishing antagonistic and agonistic anti b7-h1 antibodies
|
TWI713453B
(zh)
|
2014-06-23 |
2020-12-21 |
美商健生生物科技公司 |
干擾素α及ω抗體拮抗劑
|
CA2953807A1
(en)
|
2014-06-26 |
2015-12-30 |
Yale University |
Compositions and methods to regulate renalase in the treatment of diseases and disorders
|
CN105315375B
(zh)
|
2014-07-17 |
2021-04-23 |
恺兴生命科技(上海)有限公司 |
靶向cld18a2的t淋巴细胞及其制备方法和应用
|
US20170227541A1
(en)
|
2014-07-17 |
2017-08-10 |
The Trustees Of The University Of Pennsylvania |
Methods for using exosomes to monitor transplanted organ status
|
US10517875B2
(en)
|
2014-07-23 |
2019-12-31 |
Mayo Foundation for Medical Engineering and Research |
Targeting DNA-PKcs and B7-H1 to treat cancer
|
US10392447B2
(en)
|
2014-09-30 |
2019-08-27 |
Neurimmune Holding Ag |
Human-derived anti-dipeptide repeats (DPRs) antibody
|
US10894818B2
(en)
|
2014-10-03 |
2021-01-19 |
Massachusetts Institute Of Technology |
Antibodies that bind Ebola glycoprotein and uses thereof
|
US20170248603A1
(en)
|
2014-10-06 |
2017-08-31 |
Dana-Farber Cancer Institute, Inc. |
Angiopoiten-2 biomarkers predictive of anti-immune checkpoint response
|
CA2963602A1
(en)
|
2014-10-09 |
2016-04-14 |
Dana-Farber Cancer Institute, Inc. |
Multiple-variable il-2 dose regimen for treating immune disorders
|
WO2016081835A2
(en)
|
2014-11-21 |
2016-05-26 |
University Of Maryland, Baltimore |
Targeted structure-specific particulate delivery systems
|
WO2016087889A1
(en)
|
2014-12-03 |
2016-06-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions using orexins (oxa, oxb) for the treatment of prostate cancers
|
EP3256148A1
(en)
|
2015-02-12 |
2017-12-20 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease
|
EP3265825A4
(en)
|
2015-03-06 |
2018-08-08 |
Dana-Farber Cancer Institute, Inc. |
Pd-l2 biomarkers predictive of pd-1 pathway inhibitor responses in esophagogastric cancers
|
EP3067062A1
(en)
|
2015-03-13 |
2016-09-14 |
Ipsen Pharma S.A.S. |
Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament
|
EP3271397B1
(en)
|
2015-03-18 |
2021-03-03 |
The Johns Hopkins University |
Inhibitory monoclonal antibody targeting potassium channel kcnk9
|
EP3273981B1
(en)
|
2015-03-24 |
2020-04-29 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Method and pharmaceutical composition for use in the treatment of diabetes
|
WO2016156557A1
(en)
|
2015-04-03 |
2016-10-06 |
Alienor Farma |
Monoclonal antibody to human line-1 orf2 protein and method for early detection of transforming cells in pre-neoplastic tissues of a human subject
|
US10851176B2
(en)
|
2015-04-13 |
2020-12-01 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods of administering neutralizing anti-protease nexin-1 antibodies to treat hemophilia A
|
EP3286221A1
(en)
|
2015-04-22 |
2018-02-28 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical compositions for the treatment of th17 mediated diseases
|
EP3303591B1
(en)
|
2015-06-01 |
2019-04-03 |
Medigene Immunotherapies GmbH |
T cell receptor library
|
CA2987871A1
(en)
|
2015-06-01 |
2016-12-08 |
Medigene Immunotherapies Gmbh |
Method for generating antibodies against t cell receptor
|
US20180256716A1
(en)
|
2015-06-01 |
2018-09-13 |
Medigene Immunotherapies Gmbh |
T-cell receptor specific antibodies
|
EP3954394A1
(en)
|
2015-06-19 |
2022-02-16 |
Centurion BioPharma Corporation |
Delivery systems for controlled drug release
|
WO2016210241A1
(en)
|
2015-06-26 |
2016-12-29 |
Beth Israel Deaconess Medical Center, Inc. |
Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells
|
HUE061408T2
(hu)
|
2015-06-29 |
2023-06-28 |
Daiichi Sankyo Co Ltd |
Eljárás antitest-gyógyszer konjugátum szelektív elõállítására
|
ES2944982T3
(es)
|
2015-08-05 |
2023-06-27 |
Janssen Biotech Inc |
Anticuerpos anti-CD154 y métodos para utilizarlos
|
US11078251B2
(en)
|
2015-09-18 |
2021-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
T cell receptors (TCR) and uses thereof for the diagnosis and treatment of diabetes
|
WO2017050793A1
(en)
|
2015-09-22 |
2017-03-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Polypeptides capable of inhibiting the binding between leptin and neuropilin-1
|
EP3660051A1
(en)
|
2015-09-24 |
2020-06-03 |
Daiichi Sankyo Company, Limited |
Anti-garp antibody
|
JP2018529351A
(ja)
|
2015-09-30 |
2018-10-11 |
ヤンセン バイオテツク,インコーポレーテツド |
ヒトcd40に特異的に結合するアンタゴニスト抗体及び使用方法
|
JP6857360B2
(ja)
|
2015-10-08 |
2021-04-14 |
国立大学法人東海国立大学機構 |
キメラ抗原受容体を発現する遺伝子改変t細胞の調製方法
|
WO2017064716A1
(en)
|
2015-10-13 |
2017-04-20 |
Rappaport Family Institute For Research |
Heparanase-neutralizing monoclonal antibodies
|
US20180305458A1
(en)
|
2015-10-16 |
2018-10-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases
|
CA3002765C
(en)
|
2015-10-26 |
2023-02-28 |
Pierre Fabre Medicament |
Composition for the treatment of igf-1r expressing cancer
|
WO2017075045A2
(en)
|
2015-10-30 |
2017-05-04 |
Mayo Foundation For Medical Education And Research |
Antibodies to b7-h1
|
ITUB20155272A1
(it)
|
2015-11-02 |
2017-05-02 |
Scuola Normale Superiore |
Intracellular antibody
|
JP2019503985A
(ja)
|
2015-11-03 |
2019-02-14 |
グリコミメティクス, インコーポレイテッド |
モノクローナル抗体、造血幹細胞の産生のための方法および組成物、ならびにそれらを使用する方法
|
EA201891093A1
(ru)
|
2015-11-03 |
2018-10-31 |
Янссен Байотек, Инк. |
Антитела, специфически связывающие pd-1, и их применение
|
ITUB20155097A1
(it)
|
2015-11-05 |
2017-05-05 |
Biouniversa Srl |
Anticorpi umanizzati anti-BAG3
|
EP3386542B1
(en)
|
2015-12-10 |
2020-11-18 |
Katholieke Universiteit Leuven |
Anti adamts13 antibodies and their use for treatment or prevention of haemorrhagic disorders due to ventricular assist device
|
CN108713027A
(zh)
|
2015-12-17 |
2018-10-26 |
詹森生物科技公司 |
特异性结合hla-dr的抗体及其用途
|
GB201522394D0
(en)
|
2015-12-18 |
2016-02-03 |
Ucb Biopharma Sprl |
Antibodies
|
TWI752930B
(zh)
|
2015-12-23 |
2022-01-21 |
德商梅迪基因免疫治療公司 |
抗原特異性tcr的新生成
|
SG11201805141QA
(en)
|
2015-12-31 |
2018-07-30 |
Progastrine Et Cancers S A R L |
Compositions and methods for detecting and treating gastric cancer
|
PL3397964T3
(pl)
|
2015-12-31 |
2022-02-07 |
Progastrine Et Cancers S.À R.L. |
Kompozycje i sposoby do wykrywania i leczenia raka jajnika
|
EP3397967B1
(en)
|
2015-12-31 |
2020-12-30 |
Progastrine et Cancers S.à r.l. |
Compositions and methods for detecting and treating esophageal cancer
|
EP3202788A1
(en)
|
2016-02-05 |
2017-08-09 |
MediaPharma S.r.l. |
Endosialin-binding antibody
|
EP3416688B1
(en)
|
2016-02-15 |
2022-08-17 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Apelin for use in the treatment of post-operative cognitive dysfunction
|
EP3205663A1
(en)
|
2016-02-15 |
2017-08-16 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Means and methods for inhibiting gene expression
|
ES2903280T3
(es)
|
2016-03-01 |
2022-03-31 |
Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd |
Anticuerpos específicos del receptor de poliovirus humano (RPH)
|
US11340233B2
(en)
|
2016-03-07 |
2022-05-24 |
Pierre Fabre Medicament |
Universal method to capture and analyze ADCs for characterization of drug distribution and the drug-to-antibody ratio in biological samples
|
WO2017156263A1
(en)
|
2016-03-09 |
2017-09-14 |
Memorial Sloan-Kettering Cancer Center |
Enigma and cdh18 as companion diagnostics for cdk4 inhibitors
|
EP3779447B1
(en)
|
2016-03-15 |
2023-02-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method to activate the anti-tumoral cd8+t cell response of a patient affected with a cancer
|
WO2017158396A1
(en)
|
2016-03-16 |
2017-09-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cytidine deaminase inhibitors for the treatment of pancreatic cancer
|
EP3433615A1
(en)
|
2016-03-21 |
2019-01-30 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Methods for diagnosis and treatment of solar lentigo
|
CN108779180B
(zh)
|
2016-03-23 |
2020-10-16 |
迈博斯生物医药(苏州)有限公司 |
新型抗-pd-l1抗体
|
PT3436461T
(pt)
|
2016-03-28 |
2024-01-23 |
Incyte Corp |
Compostos de pirrolotriazina como inibidores de tam
|
ITUA20162242A1
(it)
|
2016-04-01 |
2017-10-01 |
St Biochimico Italiano Giovanni Lorenzini Spa |
Un nuovo anticorpo anti-erbb2
|
JP6907229B2
(ja)
|
2016-04-18 |
2021-07-21 |
ファロン ファーマシューティカルズ オサケ ユキチュア |
ヒト化抗clever−1抗体およびその使用
|
US11406686B2
(en)
|
2016-05-03 |
2022-08-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of tissue lesions with CCR2 agonists
|
ES2914118T3
(es)
|
2016-05-11 |
2022-06-07 |
Amgen Inc |
Selección directa de células que expresan niveles altos de proteínas heterodiméricas usando vectores de complementación intragénica de glutamina sintetasa
|
WO2017198811A1
(de)
|
2016-05-20 |
2017-11-23 |
Christoph Karl |
Pharmazeutische zusammensetzungen mit anti-rankl-antikörpern, kalzium und vitamin d, geeignet zur behandlung und/oder prophylaxe von erkrankungen des knochenstoffwechsels und von therapiebedingten nebenwirkungen wie hypokalzämien
|
WO2017202814A1
(en)
|
2016-05-24 |
2017-11-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of neuropathological disorders characterized by a loss of cortical neurons
|
WO2017202813A1
(en)
|
2016-05-24 |
2017-11-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of pulmonary bacterial infections
|
US20190307797A1
(en)
|
2016-06-07 |
2019-10-10 |
Maax-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft |
Chimeric antigen receptor and car-t cells that bind bcma
|
GB201610198D0
(en)
|
2016-06-10 |
2016-07-27 |
Ucb Biopharma Sprl |
Anti-ige antibodies
|
EP3482210B1
(en)
|
2016-07-06 |
2021-06-23 |
Prothena Biosciences Limited |
Assay for detecting total and s129 phosphorylated alpha-synuclein
|
JP2018035137A
(ja)
|
2016-07-13 |
2018-03-08 |
マブイミューン ダイアグノスティックス エイジーMabimmune Diagnostics Ag |
新規な抗線維芽細胞活性化タンパク質(fap)結合薬剤およびその使用
|
US20190330318A1
(en)
|
2016-07-25 |
2019-10-31 |
Biogen Ma Inc. |
Anti-hspa5 (grp78) antibodies and uses thereof
|
EP3491387A1
(en)
|
2016-07-28 |
2019-06-05 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Methods of treatement of cancer disease by targetting tumor associated macrophage
|
SG11201900746RA
(en)
|
2016-08-12 |
2019-02-27 |
Janssen Biotech Inc |
Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
|
KR102554331B1
(ko)
|
2016-08-12 |
2023-07-10 |
얀센 바이오테크 인코포레이티드 |
향상된 효능적 활성을 갖는 Fc 조작된 항-TNFR 수퍼패밀리 구성원 항체 및 그의 사용 방법
|
US11136409B2
(en)
|
2016-09-20 |
2021-10-05 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for identification, assessment, prevention, and treatment of AML using USP10 biomarkers and modulators
|
CN109789211A
(zh)
|
2016-10-07 |
2019-05-21 |
第一三共株式会社 |
基于抗her2抗体-药物偶联物施予的耐性癌的治疗
|
EP3527225A4
(en)
|
2016-10-12 |
2020-06-10 |
Daiichi Sankyo Company, Limited |
COMPOSITION CONTAINING ANTI-ROBO4 ANTIBODY AND OTHER AGENT
|
CR20210094A
(es)
|
2016-10-13 |
2021-03-31 |
Massachusetts Inst Technology |
ANTICUERPOS QUE SE UNEN A LA PROTEÍNA DE ENVOLTURA DEL VIRUS ZIKA Y USOS DE LOS MISMOS (Divisional 2019-0193)
|
IT201600111877A1
(it)
|
2016-11-07 |
2018-05-07 |
Biouniversa Srl |
Anti-BAG3 antibodies in combination with inhibitors of immune check-point for therapeutic use
|
EP3543337B1
(en)
|
2016-11-18 |
2022-04-20 |
Astellas Pharma Inc. |
Novel anti-human muc1 antibody fab fragment
|
SG10201912575RA
(en)
|
2016-12-12 |
2020-02-27 |
Daiichi Sankyo Co Ltd |
Combination of antibody-drug conjugate and immune checkpoint inhibitor
|
EP3556773A4
(en)
|
2016-12-13 |
2020-08-19 |
Astellas Pharma Inc. |
ANTIBODIES TO HUMAN CD73
|
CN110300761B
(zh)
|
2016-12-15 |
2023-05-09 |
国家生物技术研究所公司 |
抗pcna单克隆抗体及其用途
|
CA3048174A1
(en)
|
2016-12-22 |
2018-06-28 |
Daiichi Sankyo Company, Limited |
Anti-cd3 antibody and molecules comprising the antibody
|
US20180179490A1
(en)
|
2016-12-27 |
2018-06-28 |
Miltenyi Biotec Gmbh |
CELL COMPOSITION DEPLETED FROM TCRab and CD45RA POSITIVE CELLS
|
WO2018129284A1
(en)
|
2017-01-05 |
2018-07-12 |
The Johns Hopkins University |
Development of new monoclonal antibodies recognizing human prostate-specific membrane antigen (psma)
|
TWI780104B
(zh)
|
2017-01-17 |
2022-10-11 |
日商第一三共股份有限公司 |
抗gpr20抗體及抗gpr20抗體-藥物結合物、以及其製造方法及用途
|
WO2018140510A1
(en)
|
2017-01-25 |
2018-08-02 |
Biogen Ma Inc. |
Compositions and methods for treatment of stroke and other cns disorders
|
TW201837174A
(zh)
|
2017-02-07 |
2018-10-16 |
日商第一三共股份有限公司 |
抗gprc5d抗體及包含該抗體之分子
|
EP3363459A1
(en)
|
2017-02-17 |
2018-08-22 |
Alexander Klimka |
Polypeptide epitopes of s. aureus and respective monoclonal antibodies for the treatment of infections and immune-diagnosis
|
CA3092434A1
(en)
|
2017-02-27 |
2018-08-30 |
Caerus Therapeutics, Inc. |
Compositions of a novel anti-human ceacam6 antibody and uses thereof
|
JP7181181B2
(ja)
|
2017-02-28 |
2022-11-30 |
第一三共株式会社 |
抗her3抗体-薬物コンジュゲート投与によるegfr-tki抵抗性の非小細胞肺癌の治療方法
|
CN114940713B
(zh)
|
2017-03-15 |
2024-04-30 |
清华大学 |
抗trkb抗体
|
JOP20180021A1
(ar)
|
2017-03-16 |
2019-01-30 |
Janssen Biotech Inc |
الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها
|
US11879014B2
(en)
|
2017-03-17 |
2024-01-23 |
Tusk Therapeutics Ltd. |
Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
|
WO2018167283A1
(en)
|
2017-03-17 |
2018-09-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
|
CN110678753B
(zh)
|
2017-03-30 |
2023-10-24 |
普莱戈斯瑞恩癌症有限责任公司 |
用于治疗肺癌的组合物和方法
|
TWI782000B
(zh)
|
2017-03-30 |
2022-11-01 |
日商第一三共股份有限公司 |
抗gpr20抗體、其製造方法及其應用
|
EA201992318A1
(ru)
|
2017-03-30 |
2020-03-05 |
Прогастрин Э Кансер С.А Р.Л. |
Композиции и способы для диагностики и лечения рака предстательной железы с использованием молекулы, связывающей прогастрин
|
US10722589B2
(en)
|
2017-04-03 |
2020-07-28 |
Covagen Ag |
FGFR3 binding molecules
|
WO2018185516A1
(en)
|
2017-04-05 |
2018-10-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
|
US20200088732A1
(en)
|
2017-04-13 |
2020-03-19 |
INSERM (Institut National de la Santé et de la Recherche Mèdicale) |
Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
|
WO2018189403A1
(en)
|
2017-04-14 |
2018-10-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of cancer
|
US20190016810A1
(en)
|
2017-05-11 |
2019-01-17 |
Cytodyn Inc. |
Methods for treating or preventing graft-versus-host disease involving the administration of anti-ccr5 receptor agents
|
TWI794230B
(zh)
|
2017-05-15 |
2023-03-01 |
日商第一三共股份有限公司 |
抗cdh6抗體及抗cdh6抗體-藥物結合物、以及其製造方法
|
MX2019014577A
(es)
|
2017-06-05 |
2020-07-29 |
Janssen Biotech Inc |
Anticuerpos que se unen especificamente a pd-1 y metodos de uso.
|
EP3634496A4
(en)
|
2017-06-06 |
2021-09-08 |
Dana-Farber Cancer Institute, Inc. |
METHOD FOR RISING AWARENESS IN CANCER CELLS AGAINST T-CELL-MEDIATED KILLING BY MODULATING MOLECULAR SIGNAL PATHS
|
US20210145828A1
(en)
|
2017-06-29 |
2021-05-20 |
Rutgers, The State University Of New Jersey |
Compositions And Methods Targeting G12 Signaling For Bronchodilator Therapy
|
WO2019004487A1
(ja)
|
2017-06-30 |
2019-01-03 |
国立大学法人北海道大学 |
成長障害を生じない小児骨粗鬆症治療薬
|
TWI795415B
(zh)
|
2017-07-07 |
2023-03-11 |
日商安斯泰來製藥股份有限公司 |
新穎的抗人類CEACAM5抗體Fab片段
|
BR112020001255A2
(pt)
|
2017-07-21 |
2020-07-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
composições imunogênicas de neisseria meningitidis
|
SG11202000759XA
(en)
|
2017-07-27 |
2020-02-27 |
Daiichi Sankyo Co Ltd |
Anti-cd147 antibody
|
US20210024623A1
(en)
|
2017-07-28 |
2021-01-28 |
Intrepida Bio, Inc. |
Anti-bag3 antibodies as therapeutic reagent in cardiovascular disease
|
CN117050176A
(zh)
|
2017-07-31 |
2023-11-14 |
豪夫迈·罗氏有限公司 |
基于三维结构的人源化方法
|
EP3444272A1
(en)
|
2017-08-17 |
2019-02-20 |
International-Drug-Development-Biotech |
Treatment of ck8 positive cancers in relation with k-ras gene status
|
KR20200039783A
(ko)
|
2017-08-23 |
2020-04-16 |
막스-델부뤽-센트럼 퓌어 몰레쿨라레 메디친 인 데어 헬름홀츠-게마인샤프트 |
Cxcr5에 결합하는 키메라 항원 수용체 및 car-t 세포
|
SG11202000996UA
(en)
|
2017-08-23 |
2020-03-30 |
Daiichi Sankyo Co Ltd |
Antibody-drug conjugate preparation and lyophilization for same
|
SG11202001514XA
(en)
|
2017-08-31 |
2020-03-30 |
Daiichi Sankyo Co Ltd |
Novel method for producing antibody-drug conjugate
|
CN111051330A
(zh)
|
2017-08-31 |
2020-04-21 |
第一三共株式会社 |
抗体-药物缀合物的改进制备方法
|
US10610585B2
(en)
|
2017-09-26 |
2020-04-07 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and compositions for treating and preventing HIV
|
CA3126646A1
(en)
|
2017-09-29 |
2019-04-04 |
Daiichi Sankyo Company, Limited |
Antibody-pyrrolobenzodiazepine derivative conjugate
|
WO2019069561A1
(ja)
|
2017-10-03 |
2019-04-11 |
公益財団法人東京都医学総合研究所 |
インフルエンザに対する医薬
|
JP7384668B2
(ja)
|
2017-10-05 |
2023-11-21 |
第一三共株式会社 |
細胞傷害性t細胞枯渇用組成物
|
KR101966362B1
(ko)
*
|
2017-10-20 |
2019-04-05 |
주식회사 녹십자 |
항-msln 항체 및 이를 포함하는 암 치료용 약학적 조성물
|
CN111587123A
(zh)
|
2017-11-09 |
2020-08-25 |
品通治疗有限公司 |
用于生成和使用人源化构象特异性磷酸化的τ抗体的方法和组合物
|
JP7442821B2
(ja)
|
2017-11-30 |
2024-03-05 |
センチュリオン バイオファーマ コーポレイション |
メイタンシノイド系薬物送達システム
|
JP7359449B2
(ja)
|
2017-11-30 |
2023-10-11 |
センチュリオン バイオファーマ コーポレイション |
オーリスタチンe誘導体のアルブミン結合プロドラッグ
|
WO2019106126A1
(en)
|
2017-12-01 |
2019-06-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Mdm2 modulators for the diagnosis and treatment of liposarcoma
|
EP3720879B1
(en)
|
2017-12-05 |
2022-05-11 |
Progastrine et Cancers S.à r.l. |
Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer
|
WO2019121872A1
(en)
|
2017-12-20 |
2019-06-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the diagnosis and treatment of liver cancer
|
US20190225689A1
(en)
|
2018-01-22 |
2019-07-25 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-pd-1 antibodies
|
TW201940881A
(zh)
|
2018-01-26 |
2019-10-16 |
瑞士商Ecs前胃泌激素公司 |
在癌症診斷中結合前胃泌激素檢測與其他癌症生物標記的技術
|
WO2019155474A1
(en)
|
2018-02-12 |
2019-08-15 |
Hadasit Medical Research Services & Development Ltd. |
Modulation of slamf6 splice variants for cancer therapy
|
WO2019158512A1
(en)
|
2018-02-13 |
2019-08-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the prognosis and the treatment of glioblastoma
|
TW202000699A
(zh)
|
2018-02-27 |
2020-01-01 |
瑞士商Ecs前胃泌激素公司 |
將前胃泌激素作為生物標記用於免疫療法的技術
|
CN117903140A
(zh)
|
2018-02-27 |
2024-04-19 |
因赛特公司 |
作为a2a/a2b抑制剂的咪唑并嘧啶和三唑并嘧啶
|
CA3093205A1
(en)
|
2018-03-05 |
2019-09-12 |
Saitama Medical University |
Pharmaceutical composition for treating or preventing heterotopic ossification
|
US20210047696A1
(en)
|
2018-03-28 |
2021-02-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cancer
|
JP2021521445A
(ja)
|
2018-04-13 |
2021-08-26 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
前立腺癌又は乳癌を患っている患者の転帰を予測するための及び処置のための方法
|
CN112189018A
(zh)
|
2018-04-20 |
2021-01-05 |
汉诺威医学院 |
结合疱疹病毒抗原的嵌合抗原受体和car-t细胞
|
WO2019207066A1
(en)
|
2018-04-26 |
2019-10-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for the treatment of sjögren's syndrome
|
WO2019211369A1
(en)
|
2018-05-03 |
2019-11-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cancer
|
WO2019211370A1
(en)
|
2018-05-03 |
2019-11-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cancer
|
EP3790900A1
(en)
|
2018-05-09 |
2021-03-17 |
Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. |
Antibodies specific to human nectin4
|
SG11202011163SA
(en)
|
2018-05-11 |
2020-12-30 |
Astellas Pharma Inc |
Nucleic acid for treating mite allergy
|
BR112020023031A2
(pt)
|
2018-05-11 |
2021-02-09 |
Astellas Pharma Inc. |
ácido nucleico para tratar alergia a crustáceo
|
EP3795590A4
(en)
|
2018-05-17 |
2022-05-04 |
Astellas Pharma Inc. |
COMPLEX HAVING ANTI-HUMAN MUC1 ANTIBODY FAB FRAGMENT, PEPTIDE LINKER AND/OR LIGAND
|
MA52940A
(fr)
|
2018-05-18 |
2021-04-28 |
Incyte Corp |
Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b
|
WO2019224713A2
(en)
|
2018-05-24 |
2019-11-28 |
Janssen Biotech, Inc. |
Monospecific and multispecific anti-tmeff2 antibodies and there uses
|
EP3802608A2
(en)
|
2018-05-24 |
2021-04-14 |
Janssen Biotech, Inc. |
Anti-cd3 antibodies and uses thereof
|
AU2019274657A1
(en)
|
2018-05-24 |
2020-12-10 |
Janssen Biotech, Inc. |
PSMA binding agents and uses thereof
|
CA3101906A1
(en)
|
2018-05-28 |
2019-12-05 |
Daiichi Sankyo Company, Limited |
Treatment of her2-mutated cancer by administering anti-her2 antibody-drug conjugate
|
UY38247A
(es)
|
2018-05-30 |
2019-12-31 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
CA3099900A1
(en)
|
2018-05-31 |
2019-12-05 |
Daiichi Sankyo Company, Limited |
Anti-human tlr7 antibody
|
TW202016136A
(zh)
|
2018-06-01 |
2020-05-01 |
瑞士商諾華公司 |
針對bcma之結合分子及其用途
|
WO2019234099A1
(en)
|
2018-06-06 |
2019-12-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosing, predicting the outcome and treating a patient suffering from heart failure with preserved ejection fraction
|
WO2019234221A1
(en)
|
2018-06-08 |
2019-12-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia
|
CN112955464A
(zh)
|
2018-06-20 |
2021-06-11 |
因赛特公司 |
抗pd-1抗体及其用途
|
WO2019244107A1
(en)
|
2018-06-21 |
2019-12-26 |
Daiichi Sankyo Company, Limited |
Compositions including cd3 antigen binding fragments and uses thereof
|
AR117600A1
(es)
|
2018-06-29 |
2021-08-18 |
Incyte Corp |
Formulaciones de un inhibidor de axl / mer
|
WO2020007898A1
(en)
|
2018-07-04 |
2020-01-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating brain injury or neurodegenerative disease
|
WO2020022363A1
(ja)
|
2018-07-25 |
2020-01-30 |
第一三共株式会社 |
抗体-薬物コンジュゲートの効果的な製造方法
|
WO2020022475A1
(ja)
|
2018-07-27 |
2020-01-30 |
第一三共株式会社 |
抗体-薬物コンジュゲートの薬物部位を認識する蛋白質
|
JP7182308B2
(ja)
|
2018-07-27 |
2022-12-02 |
国立大学法人大阪大学 |
老化の抑制、加齢性の疾患もしくは症状の予防、改善、もしくは治療、または寿命の延長のための組成物
|
TWI822822B
(zh)
|
2018-07-31 |
2023-11-21 |
日商第一三共股份有限公司 |
抗體-藥物結合物之用途
|
CN112512587A
(zh)
|
2018-08-06 |
2021-03-16 |
第一三共株式会社 |
抗体药物缀合物和微管蛋白抑制剂的组合
|
BR112021003472A2
(pt)
|
2018-09-06 |
2021-05-18 |
Daiichi Sankyo Company, Limited |
derivado de dinucleotídeo cíclico e conjugado de anticorpo-fármaco do mesmo
|
JPWO2020059772A1
(ja)
|
2018-09-20 |
2021-08-30 |
第一三共株式会社 |
抗her3抗体−薬物コンジュゲート投与によるher3変異がんの治療
|
WO2020059847A1
(ja)
|
2018-09-21 |
2020-03-26 |
国立大学法人 東京医科歯科大学 |
ヒトhmgb1に特異的に結合するヒトモノクローナル抗体、及びそれを含有するアルツハイマー病を治療又は予防するための医薬組成物
|
US20220023438A1
(en)
|
2018-09-27 |
2022-01-27 |
Pierre Fabre Medicament |
Sulfomaleimide-based linkers and corresponding conjugates
|
BR112021005665A2
(pt)
|
2018-09-28 |
2021-06-22 |
Pierre Fabre Medicament |
novas imunocitocinas para o tratamento de câncer
|
JP7374544B2
(ja)
|
2018-10-10 |
2023-11-07 |
アステラス製薬株式会社 |
標識部-抗ヒト抗体Fabフラグメント複合体を含む医薬組成物
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
WO2020079164A1
(en)
|
2018-10-18 |
2020-04-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combination of a big-h3 antagonist and an immune checkpoint inhibitor for the treatment of solid tumor
|
JOP20210093A1
(ar)
|
2018-10-31 |
2023-01-30 |
Astellas Pharma Inc |
جسم مضاد fn14 غير متوافق مع الإنسان
|
EP3880706A1
(en)
|
2018-11-12 |
2021-09-22 |
MediaPharma S.r.l. |
Bispecific antibodies directed against human 90k and either endosialin or her3
|
WO2020100954A1
(ja)
|
2018-11-14 |
2020-05-22 |
第一三共株式会社 |
抗cdh6抗体-ピロロベンゾジアゼピン誘導体コンジュゲート
|
KR20210102341A
(ko)
|
2018-12-11 |
2021-08-19 |
다이이찌 산쿄 가부시키가이샤 |
항체-약물 컨쥬게이트와 parp 저해제의 조합
|
NL2024544B1
(en)
|
2018-12-21 |
2021-03-15 |
Aim Immunotech Inc |
Compositions And Methods For Cancer Therapy
|
AU2019407426A1
(en)
|
2018-12-21 |
2021-07-22 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugate and kinase inhibitor
|
JOP20210183A1
(ar)
|
2019-01-07 |
2023-01-30 |
Astellas Pharma Inc |
مادة اقتران تشتمل على ربيطة وشدفة Fab لجسم مضاد لـ CEACAM5
|
TW202043256A
(zh)
|
2019-01-10 |
2020-12-01 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
AU2020207664A1
(en)
|
2019-01-13 |
2021-07-22 |
University Of Rijeka Faculty Of Medicine |
Antibodies specific to human Nectin-2
|
WO2020157122A1
(en)
|
2019-01-29 |
2020-08-06 |
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Treating the causative agent in adhesiogenesis
|
TWI829857B
(zh)
|
2019-01-29 |
2024-01-21 |
美商英塞特公司 |
作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
|
AU2020221821A1
(en)
|
2019-02-13 |
2021-08-26 |
The Brigham And Women's Hospital, Inc. |
Anti-peripheral lymph node addressin antibodies and uses thereof
|
WO2020178193A1
(en)
|
2019-03-01 |
2020-09-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method of treatment of sarcoidosis
|
WO2020193441A1
(en)
|
2019-03-22 |
2020-10-01 |
Université de Paris |
New inhibitors of lrrk2/pp1 interaction
|
US20220168440A1
(en)
|
2019-03-25 |
2022-06-02 |
Daiichi Sankyo Company, Limited |
Antibody-pyrrolobenzodiazepine deprivative conjugate
|
CA3191804A1
(en)
|
2019-03-25 |
2020-10-01 |
Daiichi Sankyo Company, Limited |
Anti-her2 antibody-pyrrolobenzodiazepine derivative conjugate
|
WO2020193628A1
(en)
|
2019-03-25 |
2020-10-01 |
Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft |
Enhancement of cytolytic t-cell activity by inhibiting ebag9
|
KR20210143839A
(ko)
|
2019-03-27 |
2021-11-29 |
다이이찌 산쿄 가부시키가이샤 |
항체-피롤로벤조디아제핀 유도체 콘주게이트와 parp 저해제의 조합
|
CN113660954A
(zh)
|
2019-04-01 |
2021-11-16 |
凯奥目生物科学株式会社 |
癌症治疗用药物
|
BR112021019701A2
(pt)
|
2019-04-02 |
2021-12-14 |
Kenjockety Biotechnology Inc |
Anticorpos multiespecíficos para antígeno de câncer de bomba de efluxo e composições, reagentes, kits e métodos relacionados aos mesmos
|
WO2020212947A1
(en)
|
2019-04-19 |
2020-10-22 |
Janssen Biotech, Inc. |
Methods of treating prostate cancer with an anti- psma/cd3 antibody
|
US20220289854A1
(en)
|
2019-04-30 |
2022-09-15 |
Dana-Farber Cancer Institute, Inc. |
Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents
|
EP3969569A1
(en)
|
2019-05-14 |
2022-03-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Regulatory t cells targeted by lymphotoxin alpha blocking agent and uses thereof
|
KR20220015445A
(ko)
|
2019-05-29 |
2022-02-08 |
다이이찌 산쿄 가부시키가이샤 |
항체-약물 접합체의 투약
|
US20220332821A1
(en)
|
2019-06-24 |
2022-10-20 |
Novartis Ag |
Dosing regimen and combination therapies for multispecific antibodies targeting b-cell maturation antigen
|
KR20220040483A
(ko)
|
2019-07-26 |
2022-03-30 |
얀센 바이오테크 인코포레이티드 |
칼리크레인 관련 펩티다제 2 항원 결합 도메인을 포함하는 단백질 및 이의 용도
|
JPWO2021020282A1
(es)
|
2019-07-26 |
2021-02-04 |
|
|
WO2021019706A1
(ja)
|
2019-07-31 |
2021-02-04 |
国立大学法人信州大学 |
Car発現免疫細胞を含む細胞集団の製造方法
|
MX2022001133A
(es)
|
2019-08-01 |
2022-04-25 |
Incyte Corp |
Regimen de dosificacion para un inhibidor de indolamina 2,3-dioxigenasa (ido).
|
WO2021026028A1
(en)
|
2019-08-02 |
2021-02-11 |
Cytodyn Inc. |
Methods for treating or preventing cancers involving the administration of anti-ccr5 receptor agents
|
WO2021028921A1
(en)
|
2019-08-12 |
2021-02-18 |
Biond Biologics Ltd. |
Antibodies against ilt2 and use thereof
|
EP3792632A1
(en)
|
2019-09-16 |
2021-03-17 |
Vito NV |
Immunotherapy markers
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與entpd2抗體之組合療法
|
US20220348651A1
(en)
|
2019-09-18 |
2022-11-03 |
Novartis Ag |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
WO2021058744A1
(en)
|
2019-09-27 |
2021-04-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of müllerian inhibiting substance inhibitors for treating cancer
|
WO2021059075A1
(en)
|
2019-09-27 |
2021-04-01 |
Janssen Biotech, Inc. |
Anti-ceacam antibodies and uses thereof
|
KR20220088425A
(ko)
|
2019-10-25 |
2022-06-27 |
다이이찌 산쿄 가부시키가이샤 |
항 garp 항체와 면역 조절제의 조합
|
JP2023503851A
(ja)
|
2019-11-15 |
2023-02-01 |
プライアント・セラピューティクス・インコーポレイテッド |
インテグリン活性化のための組成物および方法
|
JOP20220116A1
(ar)
|
2019-11-18 |
2023-01-30 |
Janssen Biotech Inc |
اللقاحات المستندة إلى الطافر calr وjak2 واستخداماتها
|
EP4073123A4
(en)
*
|
2019-12-10 |
2024-01-10 |
Ccoa Therapeutics Inc |
HUMANIZED ANTIBODIES IB ALPHA (GPIBALPHA) ANTIBODIES
|
CN115135671A
(zh)
|
2019-12-20 |
2022-09-30 |
新石生物制药有限公司 |
抗白介素-23 p19的抗体及其使用方法
|
WO2021138512A1
(en)
|
2020-01-03 |
2021-07-08 |
Incyte Corporation |
Combination therapy comprising a2a/a2b and pd-1/pd-l1 inhibitors
|
WO2021140173A1
(en)
|
2020-01-10 |
2021-07-15 |
Biouniversa S.R.L. |
Methods and uses for treating fibrotic solid tumors with bags inhibitors
|
WO2021156329A1
(en)
|
2020-02-05 |
2021-08-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of treatment of cancer disease by targeting an epigenetic factor
|
TW202140012A
(zh)
|
2020-02-12 |
2021-11-01 |
比利時商健生藥品公司 |
用於治療尿路上皮癌的fgfr酪胺酸激酶抑制劑和抗pd1藥劑
|
TW202144388A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在卵巢癌中表現之新抗原及其用途
|
TW202144389A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在多發性骨髓瘤中表現之新抗原及其用途
|
CA3168070A1
(en)
|
2020-03-03 |
2021-09-10 |
Active Biotech Ab |
Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy
|
CA3168368A1
(en)
|
2020-03-06 |
2021-09-10 |
Masayuki Ishizaki |
Antibody-drug conjugate including novel cyclic dinucleotide derivative
|
IL296065A
(en)
|
2020-03-06 |
2022-10-01 |
Incyte Corp |
Combined treatment including axl/mer and pd-1/pd-l1 inhibitors
|
AU2021232853A1
(en)
|
2020-03-10 |
2022-09-22 |
Massachusetts Institute Of Technology |
Compositions and methods for immunotherapy of NPM1c-positive cancer
|
EP4233895A3
(en)
|
2020-03-13 |
2023-09-27 |
Janssen Biotech, Inc. |
Materials and methods for binding siglec-3/cd33
|
US11045546B1
(en)
|
2020-03-30 |
2021-06-29 |
Cytodyn Inc. |
Methods of treating coronavirus infection
|
CN115348971A
(zh)
|
2020-03-30 |
2022-11-15 |
国立研究开发法人国立癌症研究中心 |
抗体-药物缀合物
|
EP3889183A1
(en)
|
2020-04-01 |
2021-10-06 |
Pierre Fabre Medicament |
A protein complex comprising an immunocytokine
|
CN115768467A
(zh)
|
2020-04-06 |
2023-03-07 |
耶路撒冷希伯来大学伊森姆研究发展有限公司 |
用于治疗癌症和感染的针对NKp46的抗体及其构建体
|
WO2021228218A1
(zh)
|
2020-05-14 |
2021-11-18 |
江苏恒瑞医药股份有限公司 |
抗cd25抗体、其抗原结合片段及其医药用途
|
WO2021233962A1
(en)
|
2020-05-19 |
2021-11-25 |
Institut Curie |
Methods for the diagnosis and treatment of cytokine release syndrome
|
AU2021281828A1
(en)
|
2020-05-27 |
2023-02-02 |
Arialys Therapeutics, Inc. |
Anti-human NR1 antibody derivative
|
MX2022014938A
(es)
|
2020-05-27 |
2023-03-06 |
Janssen Biotech Inc |
Proteínas que comprenden dominios de unión al antígeno de cd3 y usos de éstas.
|
CN116529267A
(zh)
|
2020-06-04 |
2023-08-01 |
肯乔克蒂生物技术股份有限公司 |
Abcg2外排泵-癌症抗原多特异性抗体及其相关组合物、试剂、试剂盒和方法
|
WO2021260583A1
(en)
|
2020-06-24 |
2021-12-30 |
Astrazeneca Uk Limited |
Combination of antibody-drug conjugate and dna-pk inhibitor
|
EP4171651A1
(en)
|
2020-06-24 |
2023-05-03 |
AstraZeneca UK Limited |
Combination of antibody-drug conjugate and atm inhibitor
|
KR20230043109A
(ko)
|
2020-06-24 |
2023-03-30 |
아스트라제네카 유케이 리미티드 |
항체-약물 접합체 및 atr 억제제의 조합
|
WO2021260582A1
(en)
|
2020-06-24 |
2021-12-30 |
Astrazeneca Uk Limited |
Combination of antibody-drug conjugate and aurora b inhibitor
|
WO2021260578A1
(en)
|
2020-06-24 |
2021-12-30 |
Astrazeneca Uk Limited |
Combination of antibody-drug conjugate and cdk9 inhibitor
|
WO2021260139A1
(en)
|
2020-06-25 |
2021-12-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of treatment and diagnostic of pathological conditions associated with intense stress
|
CN116157417A
(zh)
|
2020-07-17 |
2023-05-23 |
第一三共株式会社 |
抗体-药物缀合物的制造方法
|
AU2021312537A1
(en)
|
2020-07-20 |
2023-03-09 |
Daiichi Sankyo Company, Limited |
Combination of (anti-HER2 antibody)-drug conjugate and her dimerization inhibitor
|
EP4188439A2
(en)
|
2020-07-29 |
2023-06-07 |
Janssen Biotech, Inc. |
Proteins comprising hla-g antigen binding domains and their uses
|
RU2764216C1
(ru)
*
|
2020-08-10 |
2022-01-14 |
Федеральное государственное бюджетное образовательное учреждение высшего образования "Чувашский государственный университет имени И.Н. Ульянова" |
Способ лечения гломерулонефритов с нефротическим синдромом рецидивирующего течения
|
CA3190634A1
(en)
|
2020-08-12 |
2022-02-17 |
Biond Biologics Ltd. |
Antibodies against ilt2 and use thereof
|
US20230321242A1
(en)
|
2020-08-24 |
2023-10-12 |
Charité - Universitätsmedizin Berlin |
Chimeric antigen receptor (car)-expressing cells recognizing cea
|
WO2022043315A1
(en)
|
2020-08-24 |
2022-03-03 |
Charité - Universitätsmedizin Berlin |
A CHIMERIC ANTIGEN RECEPTOR CONSTRUCT ENCODING A CHECKPOINT INHIBITORY MOLECULE AND AN IMMUNE STIMULATORY CYTOKINE AND CAR-EXPRESSING CELLS RECOGNIZING CD44v6
|
US20230331867A1
(en)
|
2020-09-04 |
2023-10-19 |
Novarock Biotherapeutics, Ltd. |
Nectin-4 antibodies and uses thereof
|
WO2022049273A1
(en)
|
2020-09-07 |
2022-03-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of treatment of inflammatory bowel diseases
|
KR20230066094A
(ko)
|
2020-09-12 |
2023-05-12 |
아스트라제네카 유케이 리미티드 |
항-her2 항체-약물 접합체 치료법을 위한 채점 방법
|
CA3198077A1
(en)
|
2020-10-05 |
2022-04-14 |
Chiome Bioscience Inc. |
Medicine for treating cancer
|
KR20230084163A
(ko)
|
2020-10-09 |
2023-06-12 |
아스트라제네카 유케이 리미티드 |
항체-약물 접합체와 parp1 선택적 억제제의 조합
|
CA3198590A1
(en)
|
2020-10-13 |
2022-04-21 |
Rajkumar Ganesan |
Bioengineered t cell mediated immunity, materials and other methods for modulating cluster of differentiation iv &/or viii
|
US20230416346A1
(en)
|
2020-10-21 |
2023-12-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
C-terminal sparc fragments for treating cancer
|
CA3199319A1
(en)
|
2020-10-22 |
2022-04-28 |
Janssen Biotech, Inc. |
Proteins comprising delta-like ligand 3 (dll3) antigen binding domains and their uses
|
WO2022097090A1
(en)
|
2020-11-05 |
2022-05-12 |
Novartis Ag |
Dosing regimen for combination therapies with multispecific antibodies targeting b-cell maturation antigen and gamma secretase inhibitors
|
US20240011094A1
(en)
|
2020-11-06 |
2024-01-11 |
Institut National de la Santé et de la Recherche Médicale |
Methods for diagnosis and treating polycystic ovary syndrome (pcos)
|
AU2021378152A1
(en)
|
2020-11-11 |
2023-06-22 |
Daiichi Sankyo Company, Limited |
COMBINATION OF AN ANTIBODY-DRUG CONJUGATE WITH ANTI-SIRPα ANTIBODY
|
CA3198382A1
(en)
|
2020-11-12 |
2022-05-19 |
Michiko Yamato |
Treatment of mesothelioma by administration of anti-b7-h3 antibody-drug conjugate
|
CA3200860A1
(en)
|
2020-11-16 |
2022-05-19 |
Astellas Pharma Inc. |
Anti-tspan8/anti-cd3 bispecific antibody and anti-tspan8 antibody
|
WO2022112469A1
(en)
|
2020-11-27 |
2022-06-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosis and monitoring of toxic epidermal necrolysis
|
WO2022115120A1
(en)
|
2020-11-30 |
2022-06-02 |
Incyte Corporation |
Combination therapy with an anti-cd19 antibody and parsaclisib
|
US20220241411A1
(en)
|
2020-11-30 |
2022-08-04 |
Incyte Corporation |
Combination therapy with an anti-cd19 antibody and parsaclisib
|
US20240025985A1
(en)
|
2020-12-09 |
2024-01-25 |
National University Corporation Tokyo Medical And Dental University |
Agent for Preventing or Treating Frontotemporal Lobar Degeneration
|
JP2024502005A
(ja)
|
2020-12-29 |
2024-01-17 |
インサイト・コーポレイション |
A2a/a2b阻害剤、pd-1/pd-l1阻害剤、及び抗cd73抗体を含む併用療法
|
WO2022153195A1
(en)
|
2021-01-13 |
2022-07-21 |
Memorial Sloan Kettering Cancer Center |
Anti-dll3 antibody-drug conjugate
|
CN117425501A
(zh)
|
2021-01-13 |
2024-01-19 |
纪念斯隆凯特琳癌症中心 |
抗体-吡咯并苯二氮䓬衍生物缀合物
|
WO2022153212A1
(en)
|
2021-01-13 |
2022-07-21 |
Axon Neuroscience Se |
Antibodies neutralizing sars-cov-2
|
EP4284838A2
(en)
|
2021-01-28 |
2023-12-06 |
Janssen Biotech, Inc. |
Psma binding proteins and uses thereof
|
EP4284510A1
(en)
|
2021-01-29 |
2023-12-06 |
Novartis AG |
Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
|
TW202241454A
(zh)
|
2021-02-01 |
2022-11-01 |
日商第一三共股份有限公司 |
抗體-免疫賦活化劑共軛物之新穎製造方法
|
CN116829591A
(zh)
|
2021-02-11 |
2023-09-29 |
奈克汀治疗有限公司 |
针对cd112r的抗体及其用途
|
KR20230146053A
(ko)
|
2021-02-12 |
2023-10-18 |
베링거 인겔하임 인터내셔날 게엠베하 |
보체 c3 항원 결합 단백질
|
US20220378929A1
(en)
|
2021-02-25 |
2022-12-01 |
MediBoston Limted |
Anti-her2 antibody-drug conjugates and uses thereof
|
IL305575A
(en)
|
2021-03-02 |
2023-10-01 |
Dana Farber Cancer Inst Inc |
Methods for treating red blood cell disorders
|
BR112023017365A2
(pt)
|
2021-03-12 |
2023-10-03 |
Daiichi Sankyo Co Ltd |
Glicano e método para produzir medicamento contendo glicano
|
EP4305064A1
(en)
|
2021-03-12 |
2024-01-17 |
Fibrosys S.r.l. |
Monoclonal antibodies for the treatment of viral infections
|
IL306103A
(en)
|
2021-03-24 |
2023-11-01 |
Janssen Biotech Inc |
The antibody targets CD22 and CD79B
|
CA3214440A1
(en)
|
2021-03-26 |
2022-09-29 |
Rupesh Nanjunda |
Humanized antibodies against paired helical filament tau and uses thereof
|
WO2022218998A1
(en)
|
2021-04-13 |
2022-10-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for treating hepatitis b and d virus infection
|
BR112023021297A2
(pt)
|
2021-04-14 |
2023-12-12 |
Villaris Therapeutics Inc |
Anticorpos anti-cd122 e usos dos mesmos
|
JP7365654B2
(ja)
|
2021-04-22 |
2023-10-20 |
アステラス製薬株式会社 |
抗cldn4-抗cd137二重特異性抗体
|
WO2022261183A2
(en)
|
2021-06-08 |
2022-12-15 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
|
CN113361141B
(zh)
*
|
2021-07-11 |
2022-02-18 |
西南石油大学 |
一种dna图谱算法的改进试验方法
|
KR20240049342A
(ko)
|
2021-08-27 |
2024-04-16 |
얀센 바이오테크 인코포레이티드 |
항-psma 항체 및 이의 용도
|
TW202320861A
(zh)
|
2021-09-15 |
2023-06-01 |
日商第一三共股份有限公司 |
以抗體-藥物結合物治療耐化療的癌症之方法
|
WO2023041744A1
(en)
|
2021-09-17 |
2023-03-23 |
Institut Curie |
Bet inhibitors for treating pab1 deficient cancer
|
WO2023046322A1
(en)
|
2021-09-24 |
2023-03-30 |
Janssen Pharmaceutica Nv |
Proteins comprising cd20 binding domains, and uses thereof
|
WO2023052541A1
(en)
|
2021-09-30 |
2023-04-06 |
Imcheck Therapeutics |
Combination of an anti-btn3a activating antibody and an il-2 agonist for use in therapy
|
AU2022368385A1
(en)
|
2021-10-18 |
2024-04-11 |
Daiichi Sankyo Company, Limited |
Anti-cd37 antibody-drug conjugate
|
CA3234598A1
(en)
|
2021-10-27 |
2023-05-04 |
Daniel Olive |
Butyrophilin (btn) 3a activating antibodies for use in methods for treating infectious disorders
|
EP4177266A1
(en)
|
2021-11-05 |
2023-05-10 |
Katholieke Universiteit Leuven |
Neutralizing anti-sars-cov-2 human antibodies
|
WO2023089527A1
(en)
|
2021-11-18 |
2023-05-25 |
Astrazeneca Uk Limited |
Combination of antibody-drug conjugate and parp1 selective inhibitor
|
WO2023089032A1
(en)
|
2021-11-19 |
2023-05-25 |
Institut Curie |
Methods for the treatment of hrd cancer and brca-associated cancer
|
WO2023097119A2
(en)
|
2021-11-29 |
2023-06-01 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions to modulate riok2
|
WO2023099763A1
(en)
|
2021-12-03 |
2023-06-08 |
Institut Curie |
Sirt6 inhibitors for use in treating resistant hrd cancer
|
WO2023105528A1
(en)
|
2021-12-12 |
2023-06-15 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Antibodies specific to ceacam1
|
US20230357392A1
(en)
|
2021-12-22 |
2023-11-09 |
Morphosys Ag |
Treatment Paradigm for an Anti-CD19 Antibody Therapy
|
WO2023126823A1
(en)
|
2021-12-28 |
2023-07-06 |
Astrazeneca Uk Limited |
Combination of antibody-drug conjugate and atr inhibitor
|
TW202333800A
(zh)
|
2021-12-28 |
2023-09-01 |
英商阿斯特捷利康英國股份有限公司 |
抗體-藥物結合物及rasg12c抑制劑之組合
|
WO2023152581A1
(en)
|
2022-02-09 |
2023-08-17 |
Janssen Biotech, Inc. |
Method of treating cancer with psmaxcd3 antibody
|
WO2023166081A1
(en)
|
2022-03-02 |
2023-09-07 |
Heidelberg Immunotherapeutics Gmbh |
Vaccine comprising an antibody or an fc-containing fusion protein comprising an fc part of an antibody
|
WO2023175614A1
(en)
|
2022-03-15 |
2023-09-21 |
Yeda Research And Development Co. Ltd. |
Anti glucocorticoid-induced tnfr-related (gitr) protein antibodies and uses thereof
|
WO2023175483A1
(en)
|
2022-03-16 |
2023-09-21 |
Astrazeneca Uk Limited |
A scoring method for an anti-trop2 antibody‑drug conjugate therapy
|
WO2023209591A1
(en)
|
2022-04-27 |
2023-11-02 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor
|
WO2023218378A1
(en)
|
2022-05-11 |
2023-11-16 |
Daiichi Sankyo Company, Limited |
Combination of an antibody specific for a tumor antigen and a cd47 inhibitor
|
WO2023228095A1
(en)
|
2022-05-24 |
2023-11-30 |
Daiichi Sankyo Company, Limited |
Dosage regimen of an anti-cdh6 antibody-drug conjugate
|
WO2024013724A1
(en)
|
2022-07-15 |
2024-01-18 |
Pheon Therapeutics Ltd |
Antibody-drug conjugates
|
WO2024023750A1
(en)
|
2022-07-28 |
2024-02-01 |
Astrazeneca Uk Limited |
Combination of antibody-drug conjugate and bispecific checkpoint inhibitor
|
US20240101718A1
(en)
|
2022-09-28 |
2024-03-28 |
Incyte Corporation |
Anti-pd-1/lag-3 bispecific antibodies and uses thereof
|
WO2024074498A1
(en)
|
2022-10-04 |
2024-04-11 |
Imcheck Therapeutics |
Combination of a btn3a activating antibody, a bcl2 inhibitor and hypomethylating agent for use in treating cancer
|